# NCCN Guidelines Version 1.2018 Sub-Committees

## Cervical Cancer

### Principles of Imaging

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nadeem R. Abu-Rustum, MD</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Hye Sook Chon, MD, MS</td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Christina Chu, MD</td>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td>Christine M. Fisher, MD, MPH</td>
<td>University of Colorado Cancer Center</td>
</tr>
</tbody>
</table>

*Dr. Nadeem R. Abu-Rustum, MD (Lead)*

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>David K. Gaffney, MD, PhD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Ernest Han, MD, PhD</td>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Andrea Mariani, MD</td>
<td>Mayo Clinic Cancer Center</td>
</tr>
<tr>
<td>Larissa Nekhlyudov, MD, MPH</td>
<td>Dana-Farber/Brigham and Women’s Cancer Center</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catheryn M. Yashar, MD, §/Lead</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Christine M. Fisher, MD, MPH, §/Co-Lead</td>
<td>University of Colorado Cancer Center</td>
</tr>
<tr>
<td>Kristin Bradley, MD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Shari Damast, MD</td>
<td>Yale Cancer Center/Smilow Cancer Hospital</td>
</tr>
<tr>
<td>Patricia J. Eifel, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>David K. Gaffney, MD, PhD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Wui-Jin Koh, MD</td>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
</tbody>
</table>

### Principles of Radiation

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Catheryn M. Yashar, MD, §/Lead</td>
<td>UC San Diego Moores Cancer Center</td>
</tr>
<tr>
<td>Dr. Christine M. Fisher, MD, MPH, §/Co-Lead</td>
<td>University of Colorado Cancer Center</td>
</tr>
<tr>
<td>Dr. Kristin Bradley, MD</td>
<td>University of Wisconsin Carbone Cancer Center</td>
</tr>
<tr>
<td>Dr. Shari Damast, MD</td>
<td>Yale Cancer Center/Smilow Cancer Hospital</td>
</tr>
<tr>
<td>Dr. Patricia J. Eifel, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Dr. David K. Gaffney, MD, PhD</td>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td>Dr. Wui-Jin Koh, MD</td>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
</tbody>
</table>

**NCCN Guidelines Panel Disclosures**

Version 1.2018, 10/25/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
NCCN Guidelines for Cervical Cancer include the management of squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix.

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2017.
Updates in Version 1.2018 of the NCCN Guidelines for Cervical Cancer from Version 1.2017 include:

**Global changes**
- “Concurrent cisplatin-based chemotherapy” changed to “Concurrent cisplatin-containing chemotherapy.”
- “Clinical trial” was removed throughout the algorithm, but is still listed as part of the NCCN Clinical Trials footer box noted on all pages.
- “Chemotherapy” changed to “Systemic therapy” where appropriate.
- The AJCC Cancer Staging tables (7th edition) were updated to the 8th edition for carcinoma of the cervix. (ST-1).

**CERV-1**
- Workup; Eighth bullet: “Consider HIV testing” changed from category 3 to category 2A. Corresponding footnote “c” added, “Consider HIV testing, especially in younger patients. Patients with cervical cancer and HIV should be referred to an HIV specialist and should be treated for cervical cancer as per these guidelines. Modifications to cancer treatment should not be made solely on the basis of HIV status.”
- Clinical Stage: A new pathway was added for “Stage IVB.”

**CERV-3**
- Stage IA1 no LVSI; Cone Biopsy; Positive margins for dysplasia or carcinoma: Primary treatment option revised “Consider repeat cone biopsy to better evaluate depth of invasion to rule out Stage IA2/IB1 disease”

**CERV 5**
- Adjuvant Treatment
  - Positive pelvic nodes and/or Positive surgical margin and/or Positive parametrium: Recommendation revised: “Pelvic EBRT + concurrent cisplatin-containing chemotherapy (category 1) ± vaginal brachytherapy.”
  - Para-aortic lymph node positive by surgical staging: “Consider Biopsy of suspicious areas as indicated”
  - New footnote “s” added: “Patients with high-risk pathologic features meeting Sedlis criteria and/or positive nodes are no longer candidates for fertility sparing.”

**CERV-6**
- Stage IB2, Stage IIA2; Primary Treatment after positive adenopathy found on radiologic imaging: “Consider needle biopsy” removed.

**CERV-7**
- Pelvic node positive; Para-aortic lymph node positive: “Consider extraperitoneal or laparoscopic lymph node dissection” removed as a primary treatment option.
- New footnote “u” added: “Patients with distant metastatic disease confined to the supraclavicular nodes may be treated definitively.”
CERV-8
- Para-aortic lymph node positive by surgical staging; Positive for distant metastasis after further radiologic workup: Revised, “Consider biopsy of suspicious areas as indicated.”

CERV-9 Incidental Finding of Invasive Cancer After Simple Hysterectomy
- Staging: “≥ Stage IA1 with LVSI” changed to “Stage IA1 with LVSI or Stage IA2/IB or positive margins/gross residual disease.”
- Negative margins; negative imaging; Complete parametrectomy/upper vaginectomy....”:
  ◦ Revised, “Negative nodes; No residual disease”
    • Treatment option removed: “Optional pelvic EBRT ± vaginal brachytherapy if large primary tumor, deep stromal invasion and/or LVSI”
- Revised: “Positive margins, gross residual disease, positive imaging or primary tumor characteristics meeting Sedlis criteria.” with corresponding footnote “x” referencing the Sedlis Criteria (CERV-D)
- Recommendation revised: “Pelvic EBRT (para-aortic lymph node EBRT if para-aortic lymph node positive) + concurrent cisplatin-containing chemotherapy (category 1)....”

CERV-10

CERV-11
- Local/regional recurrence; Prior RT; Noncentral disease; Therapy for Relapse:
  ◦ “Best supportive care” removed as an option.
  ◦ After the “Therapy for Relapse” treatment options, a new pathway was added for “Recurrence”. Treatment options for “Recurrence” include “Systemic Therapy or Best supportive care.”

CERV-12
- Revised:
  ◦ First column: Changed to “Stage IVB or Distant metastases.”
  ◦ Third column title changed from “Therapy for Relapse” to “Treatment.”
NCCN Guidelines Version 1.2018 Updates
Cervical Cancer

CERV-A Principles of Imaging
Page 1 of 3

• Initial Workup; Stage I
  ‣ Non-Fertility Sparing bullets revised:
    ◊ “Optional Consider pelvic MRI with contrast to assess local disease extent (preferred for FIGO stage IB2).”
    ◊ Added: “Consider whole body PET/CT or chest/abdomen/pelvic CT in FIGO Stage IB1.”
    ◊ “Consider whole body PET/CT or chest/abdomen/pelvic CT in FIGO stage IB2.”
  ‣ Fertility Sparing
    ◊ Added: “Consider whole body PET/CT or chest/abdomen/pelvic CT in FIGO Stage IB1.”

Page 2 of 3

• Follow-up/Surveillance
  ‣ Stage I; Fertility-Sparing: Removed: “Consider whole body PET/CT if metastasis is suspected.”
  ‣ Stage II-IV: Revised, “Optional Consider pelvic MRI with contrast at 3–6 months post completion of therapy.”
  • A new section added for “Suspected Recurrence or Metastasis” that includes “Consider whole body PET/CT”.

CERV-C Principles of Radiation Therapy
• This section was extensively revised.

CERV-E
• Page title changed from “Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer” to “Systemic Therapy Regimens for Cervical Cancer”.
• A new section added for “Chemoradiation (preferred regimens)” that includes “Cisplatin” and “Cisplatin/fluourouracil”
• Recurrent or Metastatic Disease; Second-line Therapy: “Pembrolizumab (for MSH-H/dMMR tumors) (category 2B)” added as an option.
• Footnote “***” regarding first-line combination therapy is new: “These agents can be used as second-line therapy if not used previously.”
WORKUP

• H&P
• Complete blood count (CBC) (including platelets)
• Cervical biopsy, pathologic review
• Cone biopsy as indicated\(^a\)
• LFT/renal function studies
• Imaging\(^b\)
• Smoking cessation and counseling intervention if indicated
• Consider HIV testing\(^c\)

Optional:
• EUA cystoscopy/proctoscopy\(^d\) (≥ stage IB2)

CLINICAL STAGE

Stage IA1

Stage IA2
Stage IB1

Stage IIA1

Stage IB2
Stage IIA2

Stage IIB
Stage IIIA, IIIB
Stage IVA

Stage IVB

Incident finding of invasive cancer at simple hysterectomy

See Primary Treatment (Fertility Sparing) (CERV-2)

See Primary Treatment (Non-Fertility Sparing) (CERV-3)

See Primary Treatment (Fertility Sparing) (CERV-2)

See Primary Treatment (Non-Fertility Sparing) (CERV-3) and (CERV-4)

See Primary Treatment (Non-Fertility Sparing) (CERV-4)

See Primary Treatment (CERV-4) and (CERV-6)

See Primary Treatment (CERV-6)

See Treatment (CERV-12)

See Treatment (CERV-9)

All staging in guideline is based on updated 2009 FIGO staging. (See ST-1)

\(^a\)See Discussion for indications for cone biopsy.

\(^b\)See Principles of Imaging (CERV-A).

\(^c\)Consider HIV testing, especially in younger patients. Patients with cervical cancer and HIV should be referred to an HIV specialist and should be treated for cervical cancer as per these guidelines. Modifications to cancer treatment should not be made solely on the basis of HIV status.

\(^d\)For suspicion of bladder/bowel involvement, cystoscopy/proctoscopy with biopsy is required.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 1.2018
#### Cervical Cancer

#### CLINICAL STAGE\(^b\)  
**PRIMARY TREATMENT (FERTILITY SPARING)\(^f\)**

| Stage IA1 | Cone biopsy\(^g\) with negative margins\(^h\)  
(preferably a non-fragmented specimen with 3-mm negative margins\(^h\))  
(if positive margins, repeat cone biopsy or perform trachelectomy) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>no lymphovascular space invasion (LVSI)</td>
<td>See Surveillance (CERV-10)</td>
</tr>
</tbody>
</table>

| Stage IA1 | Cone biopsy\(^g\) with negative margins\(^h\)  
(preferably a non-fragmented specimen with 3-mm negative margins\(^h\))  
(if positive margins, repeat cone biopsy or perform trachelectomy)  
+ pelvic lymph node dissection  
± para-aortic lymph node sampling (category 2B)  
(Consider sentinel lymph node [SLN] mapping)\(^i\)  
or  
Radical trachelectomy + pelvic lymph node dissection\(^i\)  
± para-aortic lymph node sampling [category 2B])  
(Consider SLN mapping)\(^i\) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>with LVSI and Stage IA2</td>
<td>See Surgical Findings (CERV-5)</td>
</tr>
</tbody>
</table>

| Stage IB1\(^e\) | Radical trachelectomy  
+ pelvic lymph node dissection\(^i\)  
± para-aortic lymph node sampling  
(Consider SLN mapping)\(^i,j\) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>See Surgical Findings (CERV-5)</td>
</tr>
</tbody>
</table>

\(^b\) See Principles of Imaging (CERV-A).

\(^e\) Fertility-sparing surgery for stage IB1 has been most validated for tumors ≤2 cm. Small cell neuroendocrine histology and adenoma malignum are not considered suitable tumors for this procedure.

\(^f\) There are no data to support a fertility-sparing approach in small neuroendocrine tumors, gastric type adenocarcinoma, or adenoma malignum (also known as minimal deviation adenocarcinoma). Total hysterectomy after completion of childbearing is at the patient’s and surgeon’s discretion, but is strongly advised in women with continued abnormal pap smears or chronic persistent HPV infection.

\(^g\) Cold knife conization (CKC) is the preferred method of diagnostic excision, but loop electrosurgical excision procedure (LEEP) is acceptable, provided adequate margins and proper orientation are obtained. Endocervical curettage (ECC) may be added as clinically indicated.

\(^h\) Negative for invasive disease or histologic high-grade squamous intraepithelial lesion (HSIL) at margins.

\(^i\) See Principles of Evaluation and Surgical Staging (CERV-B).

\(^j\) For SLN mapping, the best detection rates and mapping results are in tumors <2 cm.
### CLINICAL STAGE\(^b\)

<table>
<thead>
<tr>
<th>Stage IA1 no LVSI</th>
<th>Cone biopsy(^g)</th>
<th>Negative margins and inoperable</th>
<th>Observe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA1 no LVSI</td>
<td>Cone biopsy(^g)</td>
<td>Negative margins and operable</td>
<td>Extrafascial hysterectomy(^i)</td>
</tr>
<tr>
<td>Stage IA1 with LVSI and Stage IA2</td>
<td></td>
<td>Positive margins for dysplasia or carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

### BIOPSY RESULTS
- **Negative margins and inoperable**: Observe
- **Negative margins and operable**: Extrafascial hysterectomy\(^i\)
- **Positive margins for dysplasia or carcinoma**: Consider repeat cone biopsy\(^g\) to better evaluate depth of invasion to rule out Stage IA2/IB1 disease or Extrafascial or modified radical hysterectomy + pelvic lymph node dissection if margins positive for carcinoma\(^i\) (category 2B for node dissection) (Consider SLN mapping)\(^i\)

### PRIMARY TREATMENT (NON-FERTILITY SPARING)

- **Stage IA1 no LVSI**
  - Cone biopsy\(^g\)
  - Negative margins and inoperable: Observe
  - Negative margins and operable: Extrafascial hysterectomy\(^i\)
- **Stage IA1 with LVSI and Stage IA2**
  - Positive margins for dysplasia or carcinoma: Consider repeat cone biopsy\(^g\) to better evaluate depth of invasion to rule out Stage IA2/IB1 disease or Extrafascial or modified radical hysterectomy + pelvic lymph node dissection if margins positive for carcinoma\(^i\) (category 2B for node dissection) (Consider SLN mapping)\(^i\)
  - Modified radical hysterectomy + pelvic lymph node dissection\(^i\) ± para-aortic lymph node sampling (category 2B) (Consider SLN mapping)\(^i\) or Pelvic EBRT\(^k,l\) + brachytherapy\(^l,m,n\)

### Notes
- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

\(^b\)See Principles of Imaging (CERV-A).

\(^g\)Cold knife conization (CKC) is the preferred method of diagnostic excision, but loop electrosurgical excision procedure (LEEP) is acceptable, provided adequate margins and proper orientation are obtained. Endocervical curettage (ECC) should be added as clinically indicated.

\(^i\)See Principles of Evaluation and Surgical Staging (CERV-B).

\(^j\)Radiation can be an option for medically inoperable patients or those who refuse surgery.

\(^k\)See Principles of Radiation Therapy for Cervical Cancer (CERV-C).

\(^l\)These doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose-rate (40–70 cGy/h) brachytherapy equivalents. Modify treatment based on normal tissue tolerance, fractionation, and size of target volume. (See Discussion)

\(^m\)The traditional dose would be 70–80 Gy to total point A dose.
### Clinical Stage^b

**Stage IB1 and Stage IIA1**

- Radical hysterectomy + pelvic lymph node dissection\(^i\) (category 1)  
- ± para-aortic lymph node sampling (category 2B)  
  - (Consider SLN mapping)\(^{i,j}\)  
  - or  
  - Pelvic EBRT\(^{k,l}\)  
  - + brachytherapy (total point A dose: 80–85 Gy)\(^{l,m}\)  
  - ± concurrent cisplatin-containing chemotherapy\(^o\)

**Stage IB2 and Stage IIA2**  
(also see CERV-6 for additional recommendations for non-primary surgery patients)

- Definitive pelvic EBRT\(^l\)  
  - + concurrent cisplatin-containing chemotherapy\(^o\)  
  - + brachytherapy (total point A dose ≥85 Gy)\(^{l,m}\)  
  - (category 1 for primary chemoradiation)  
  - or  
  - Radical hysterectomy  
  - + pelvic lymph node dissection\(^i\)  
  - ± para-aortic lymph node sampling (category 2B)  
  - or  
  - Pelvic EBRT\(^l\)  
  - + concurrent cisplatin-containing chemotherapy\(^o\)  
  - + brachytherapy\(^{l,m,p}\)  
  - + adjuvant hysterectomy\(^q\)  
  - (category 3)

---

\(^b\)See Principles of Imaging (CERV-A).  
\(^i\)See Principles of Evaluation and Surgical Staging (CERV-B).  
\(^j\)For SLN mapping, the best detection rates and mapping results are in tumors <2 cm.  
\(^k\)Radiation can be an option for medically inoperable patients or those who refuse surgery.  
\(^l\)See Principles of Radiation Therapy for Cervical Cancer (CERV-C).  
\(^m\)These doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose-rate (40–70 cGy/h) brachytherapy equivalents. Modify treatment based on normal tissue tolerance, fractionation, and size of target volume. (See Discussion)  
\(^o\)Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.  
\(^p\)The traditional dose would be 75–80 Gy to total point A dose.  
\(^q\)This approach can be considered in patients whose extent of disease or uterine anatomy precludes adequate coverage by brachytherapy.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## NCCN Guidelines Version 1.2018
### Cervical Cancer

### SURGICAL FINDINGS

<table>
<thead>
<tr>
<th>Negative nodes, negative margins, negative parametrium</th>
<th>Observe or Pelvic EBRT(^1) if combination of high-risk factors (ie, primary tumor size, stromal invasion, and/or LVSI that meet Sedlis criteria(^1,5,6) [category 1]) ± concurrent cisplatin-containing chemotherapy(^6) (category 2B for chemotherapy)</th>
<th>See Surveillance (CERV-10)</th>
</tr>
</thead>
</table>

| Positive pelvic nodes and/or Positive surgical margin and/or Positive parametrium | EBRT\(^1\) + concurrent cisplatin-containing chemotherapy\(^6,5\) (category 1) ± vaginal brachytherapy\(^1\) | |

<table>
<thead>
<tr>
<th>Para-aortic lymph node positive by surgical staging</th>
<th>Imaging workup for metastatic disease(^b)</th>
<th></th>
</tr>
</thead>
</table>

### ADJUVANT TREATMENT

<table>
<thead>
<tr>
<th>Negative for distant metastasis</th>
<th>Para-aortic lymph node EBRT(^1) + concurrent cisplatin-containing chemotherapy(^6) + pelvic EBRT(^1) ± brachytherapy(^1)</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Positive for distant metastasis</th>
<th>Biopsy suspicious areas as indicated</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Biopsy suspicious areas as indicated</th>
<th>Negative</th>
<th></th>
</tr>
</thead>
</table>

| Positive for distant metastasis | Chemotherapy\(^t\) ± individualized EBRT\(^1\) | |

\(b\) See Principles of Imaging (CERV-A).
\(1\) See Principles of Radiation Therapy for Cervical Cancer (CERV-C).
\(6\) Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
\(t\) Risk factors may not be limited to the Sedlis criteria. See Sedlis Criteria (CERV-D).
\(5\) Patients with high-risk pathologic features meeting Sedlis criteria and/or positive nodes are no longer candidates for fertility sparing.
\(1\) See Systemic Therapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-E).

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**Clinical Stage**

- **Stage IB2, Stage IIA2**
  - (See CERV-4 for alternative recommendations for these patients)
  - Stage IIB, IIIA, IIIB, IVA

**Additional Workup**

- Radiologic imaging only
  - **Positive adenopathy** → See Imaging Results (CERV-7)
  - **Negative adenopathy**
    - Surgical staging (category 2B): Extraperitoneal or laparoscopic lymph node dissection
      - **Negative** → Pelvic EBRT\(^\text{I}\) + concurrent cisplatin-containing chemotherapy\(^\text{O}\) + brachytherapy\(^\text{I}\) (category 1)
      - **Positive** → See Node Status (CERV-8)

**Primary Treatment**

- Pelvic EBRT\(^\text{I}\) + concurrent cisplatin-containing chemotherapy\(^\text{O}\) + brachytherapy\(^\text{I}\) (category 1)

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

- **See Principles of Imaging (CERV-A).**
- **See Principles of Radiation Therapy for Cervical Cancer (CERV-C).**
- Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
Stage IB2, IIA2
Stage IIB, IIIA, IIIB, IVA
IMAGING RESULTS

Positive adenopathy by CT, MRI, and/or PET

Pelvic node positive; Para-aortic lymph node negative

Pelvic EBRT\(^1\) + concurrent cisplatin-containing chemotherapy\(^0\) + brachytherapy\(^i\) (category 1) ± para-aortic lymph node EBRT\(^l\)

or

Extraperitoneal or laparoscopic lymph node dissection\(^v\)

Para-aortic negative

Para-aortic positive

Extended-field EBRT\(^l\) + concurrent cisplatin-containing chemotherapy\(^o\) + brachytherapy\(^l\)

Pelvic EBRT\(^l\) + concurrent cisplatin-containing chemotherapy\(^o\) + brachytherapy\(^l\) (category 1)

Distant metastases\(^u\) with biopsy confirmation as clinically indicated

Chemotherapy\(^\dagger\) ± individualized RT\(^l\)

See Surveillance (CERV-10)

See Principles of Imaging (CERV-A).
See Principles of Radiation Therapy for Cervical Cancer (CERV-C).
Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
See Systemic Therapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-E).

Patients with distant metastatic disease confined to the surpaclavicular nodes may be treated definitively.

Consider postoperative imaging (abdominal/pelvic CT or MRI with contrast) to confirm the adequacy of node removal.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Stage IB2, IIA2; Stage IIB, IIIA, IIIB, IVA

**NODE STATUS**

**Pelvic lymph node positive** and **para-aortic lymph node negative by surgical staging**

**PRIMARY TREATMENT**

- Pelvic EBRT\(^1\)
  - + concurrent cisplatin-containing chemotherapy\(^o\)
  - + brachytherapy\(^l\)
  - (category 1)

**Para-aortic lymph node positive by surgical staging**

Further radiologic workup for metastatic disease as clinically indicated\(^b\)

**Negative for distant metastasis**

- Biopsy suspicious areas as indicated

**Positive for distant metastasis**

- Systemic therapy\(^t\)
  - ± individualized RT\(^l\)

- Biopsy suspicious areas as indicated

**Positive**

- Systemic therapy\(^t\)
  - ± individualized RT\(^l\)

**Biopsy**

- Negative

- Positive

---

\(^b\)See Principles of Imaging (CERV-A).

\(^l\)See Principles of Radiation Therapy for Cervical Cancer (CERV-C).

\(^o\)Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

\(^t\)See Systemic Therapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-E).

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**INCIDENTAL FINDING OF INVASIVE CANCER AFTER SIMPLE HYSTERECTOMY**

**Stage IA1**
- Pathologic review
- No LVSI

**Pelvic EBRT**, [brachytherapy], ± concurrent cisplatin-containing chemotherapy

- Negative margins; negative imaging
- or
- Complete parametrectomy/upper vaginectomy + pelvic lymph node dissection
  - ± para-aortic lymph node sampling (category 2B for para-aortic lymph node sampling)

**Stage IA1 with LVSI or Stage IA2/IB or Positive margins/ gross residual disease**
- • H&P
- • CBC (including platelets)
- • LFT/renal function studies
- • Imaging
- Positive margins, gross residual disease, positive imaging or primary tumor characteristics meeting Sedlis criteria

**Imaging negative for nodal disease**

**Imaging positive for nodal disease**
- Consider surgical debulking of grossly enlarged nodes

**Positive nodes and/or Positive surgical margin and/or Positive parametrium**
- Pelvic EBRT, (para-aortic lymph node EBRT if para-aortic lymph node positive)
  - + concurrent cisplatin-containing chemotherapy
  - (category 1)
  - ± individualized brachytherapy

**Negative nodes; No residual disease**
- Observe

**Negative margins; negative imaging**

**Version 1.2018, 10/25/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.**

*Note: All recommendations are category 2A unless otherwise indicated.*

*Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.*
**SURVEILLANCE**

- Interval H&P  
  - every 3–6 mo for 2 y,  
  - every 6–12 mo for 3–5 y,  
  - then annually based on patient’s risk of disease recurrence
- Cervical/vaginal cytology annually as indicated for the detection of lower genital tract neoplasia
- Imaging as indicated based on symptoms or examination findings suspicious for recurrence
- Laboratory assessment (CBC, blood urea nitrogen [BUN], creatinine) as indicated based on symptoms or examination findings suspicious for recurrence
- Patient education regarding symptoms of potential recurrence, periodic self-examinations, lifestyle, obesity, exercise, sexual health (including vaginal dilator use and lubricants/moisturizers), smoking cessation, nutrition counseling, and potential long-term and late effects of treatment (See NCCN Guidelines for Survivorship and NCCN Guidelines for Smoking Cessation)

**WORKUP**

- Persistent or recurrent disease
  - Additional imaging as clinically indicated
  - Surgical exploration in selected cases

### See Therapy for Relapse (Local/Regional Recurrence) (CERV-11)

### See Therapy for Relapse (Distant Metastases) (CERV-12)

---

*b* See Principles of Imaging (CERV-A).


*z* Regular cytology can be considered for detection of lower genital tract dysplasia, although its value in detection of recurrent cervical cancer is limited. The likelihood of picking up asymptomatic recurrences by cytology alone is low.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
THERAPY FOR RELAPSE

No prior RT or failure outside of previously treated field

<table>
<thead>
<tr>
<th>Consider surgical resection, if feasible</th>
<th>Individualized EBRT(^1) ± systemic therapy(^{o,t}) ± brachytherapy(^1)</th>
<th>Recurrence</th>
</tr>
</thead>
</table>

Pelvic exenteration ± intraoperative RT (IORT)\(^1\) (category 3 for IORT)

<table>
<thead>
<tr>
<th>or</th>
<th>Recurrence</th>
</tr>
</thead>
</table>

In carefully selected patients with small (<2 cm) lesions

<table>
<thead>
<tr>
<th>Radical hysterectomy or Brachytherapy(^1)</th>
<th>Recurrence</th>
</tr>
</thead>
</table>

Individualized EBRT\(^1\) ± systemic therapy\(^{o,t}\) or Resection ± IORT\(^1\) (category 3 for IORT) or Systemic therapy\(^t\)

<table>
<thead>
<tr>
<th>or</th>
<th>Recurrence</th>
</tr>
</thead>
</table>

Central disease

Prior RT

Noncentral disease

Local/regional recurrence

\(^1\)See Principles of Radiation Therapy for Cervical Cancer (CERV-C).

\(^{o}\)Concurrent cisplatin-based chemotherapy with EBRT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

\(^{t}\)See Systemic Therapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-E).

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2018
Cervical Cancer

TREATMENT

Stage IVB or Distant metastases

Amenable to local treatment

- Local treatment:
  - Resection
    ± Individualized EBRT
  or
  - Local ablative therapies
    ± Individualized EBRT
  or
  - Individualized EBRT
    ± systemic therapy
  - Consider adjuvant systemic therapy

Not amenable to local treatment

Systemic therapy
or
Best supportive care
(See NCCN Guidelines for Palliative Care)

See Surveillance (CERV-10)

1See Principles of Radiation Therapy for Cervical Cancer (CERV-C).
2See Systemic Therapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-E).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Initial Workup

• Stage I
  † Non-Fertility Sparing
    ◊ Consider chest imaging with plain radiography (chest x-ray). If an abnormality is seen then chest CT without contrast may be performed.
    ◊ Consider pelvic MRI with contrast to assess local disease extent (preferred for FIGO stage IB2).
    ◊ Consider whole body PET/CT or chest/abdomen/pelvic CT in FIGO Stage IB1
    ◊ Whole body PET/CT or chest/abdomen/pelvic CT in FIGO stage IB2.
    ◊ For patients who underwent total hysterectomy (TH) with incidental finding of cervical cancer, consider whole body PET/CT or chest/abdomen/pelvic CT to evaluate for metastatic disease and pelvic MRI to assess pelvic residual disease.
  † Fertility Sparing
    ◊ Consider chest imaging with plain radiography (chest x-ray). If an abnormality is seen then chest CT without contrast may be performed.
    ◊ Pelvic MRI (preferred) to assess local disease extent and proximity of tumor to internal cervical os; pelvic transvaginal ultrasound if MRI contraindicated.
    ◊ Consider whole body PET/CT or chest/abdomen/pelvic CT in FIGO Stage IB1.
    ◊ Other imaging should be based on symptomatology and clinical concern for metastatic disease.

• Stage II-IV
  † Whole body PET/CT (preferred) or chest/abdomen/pelvic CT to evaluate for metastatic disease.
  † Consider pelvic MRI with contrast to assess local disease extent.
  † Other initial imaging should be based on symptomatology and clinical concern for metastatic disease.
  † For patients who underwent TH with incidental finding of cervical cancer consider whole body PET/CT or chest/abdomen/pelvic CT to evaluate for metastatic disease and pelvic MRI with contrast to assess pelvic residual disease.

*MRI and CT are performed with contrast throughout the guidelines unless contraindicated. Contrast is not required for screening chest CT.
**These factors may include abnormal physical exam findings or pelvic, abdominal, or pulmonary symptoms.
***These factors may include abnormal physical exam findings, bulky pelvic tumor (>4 cm), delay in presentation or treatment, and pelvic abdominal or pulmonary symptoms.
### Follow-up/Surveillance

**Stage I**
- **Non-Fertility Sparing**
  - Imaging should be based on symptomatology and clinical concern for recurrent/metastatic disease.**
  - For patients with FIGO stage IB2 or patients who required postoperative adjuvant radiation or chemoradiation due to high-risk factors,† a whole body PET/CT may be performed at 3–6 months after completion of treatment.
- **Fertility-Sparing**
  - Consider pelvic MRI with contrast 6 months after surgery and then yearly for 2–3 years.
  - Other imaging should be based on symptomatology and clinical concern for recurrent/metastatic disease.**

**Stage II-IV**
- Whole body PET/CT (preferred) or chest/abdomen/pelvic CT with contrast within 3–6 months of completion of therapy.
- Consider pelvic MRI with contrast at 3–6 months post completion of therapy.
- Other imaging should be based on symptomatology and clinical concern for recurrent/metastatic disease.††

### Suspected Recurrence or Metastasis
- Consider whole body PET/CT.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*MRI and CT are performed with contrast throughout the guidelines unless contraindicated. Contrast is not required for screening chest CT.

**These factors may include abnormal physical exam findings or new pelvic, abdominal, or pulmonary symptoms.

†These factors may include positive nodes, positive parametria, positive margins, or local cervical factors (See Sedlis Criteria CERV-D).

††These factors may include abnormal physical exam findings such as palpable mass or adenopathy, or new pelvic, abdominal, or pulmonary symptoms.
PRINCIPLES OF IMAGING
(References)


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING

Types of Resection and Appropriateness for Treatment of Cervical Cancer

• Treatment of cervical cancer is stratified by stage as delineated in the Guidelines.

• Microinvasive disease, defined as FIGO stage IA-1 with no lymphovascular space invasion (LVSI), has less than a 1% chance of lymphatic metastasis and may be managed conservatively with cone biopsy for preservation of fertility (with negative margins) or with simple hysterectomy when preservation of fertility is not desired or relevant. The intent of a cone biopsy is to remove the ectocervix and endocervical canal en bloc using a scalpel. This provides the pathologist with an intact, non-fragmented specimen without electrosurgical artifact, which facilitates margin status evaluation. If a loop electrosurgical excision procedure (LEEP) is chosen for treatment, the specimen should not be fragmented, and care must be undertaken to minimize electrosurgical artifact at the margins. The shape and depth of the cone biopsy may be tailored to the size, type, and location of the neoplastic lesion. For example, if there is concern for invasive adenocarcinoma versus adenocarcinoma in situ in the cervical canal, the cone biopsy would be designed as a narrow, long cone extending to the internal os in order not to miss possible invasion in the endocervical canal. Cone biopsy is indicated for triage and treatment of small cancers where there is no likelihood of cutting across gross neoplasm. In cases of stage IA1 with LVSI, a conization (with negative margins) with laparoscopic pelvic SLN mapping/lymphadenectomy is a reasonable strategy.

• Radical hysterectomy with bilateral pelvic lymph node dissection (with or without SLN mapping) is the preferred treatment for FIGO stage IA-2, IB, and IIA lesions when fertility preservation is not desired. Radical hysterectomy results in resection of much wider margins compared with a simple hysterectomy, including removal of parts of the cardinal and uterosacral ligaments and the upper 1–2 cm of the vagina; in addition, pelvic and sometimes para-aortic nodes are removed. Radical hysterectomy procedures may be performed either via laparotomy or laparoscopy, and the laparoscopy approach may be either with conventional or robotic techniques. The Querleu & Morrow classification system is a modern surgical classification that describes degree of resection and nerve preservation in 3-dimensional planes of resection. Procedural details for the most commonly used types of hysterectomy are described in Table 1 (see CERV-B 5 of 7).

• The radical vaginal trachelectomy with laparoscopic lymphadenectomy procedure (with or without SLN mapping) offers a fertility-sparing option for carefully selected individuals with stage IA-2 or stage IB-1 lesions of 2 cm diameter or less. The cervix, upper vagina, and supporting ligaments are removed as with a type B radical hysterectomy, but the uterine corpus is preserved. In the more than 300 subsequent pregnancies currently reported, there is a 10% likelihood of second trimester loss, but 72% of patients carry their gestation to 37 weeks or more. The abdominal radical trachelectomy has emerged as a reasonable fertility-sparing strategy. It provides larger resection of parametria than the vaginal approach, is suitable for select stage IB1 cases, and has been utilized in lesions up to 4 cm in diameter. The operation mimics a type C radical hysterectomy.*

*For a description of a type C radical hysterectomy, see Table 1 (CERV-B 5 of 7).
PRINCIPLES OF EVALUATION AND SURGICAL STAGING

Types of Resection and Appropriateness for Treatment of Cervical Cancer--continued

- Advanced-stage disease, including FIGO stage IIB and above, is not usually treated with hysterectomy, as delineated in the Guidelines. The majority of advanced-stage disease in the United States is treated with definitive chemoradiation. In some countries, select cases of stage IIB may be treated with upfront radical hysterectomy or neoadjuvant chemotherapy followed by radical hysterectomy.

- Recurrent or persistent disease in the central pelvis following radiation therapy may potentially be cured with the pelvic exenteration procedure. Preoperative assessment for exenteration is designed to identify or rule out distant metastasis. If the recurrence is confined to the pelvis, then surgical exploration is carried out. If intraoperative margin and node assessment are negative, then resection of pelvic viscera is completed. Depending on the location of the tumor, resection may include anterior exenteration, posterior exenteration, or total pelvic exenteration. In cases where the location of tumor allows adequate margins, the pelvic floor and anal sphincter may be preserved as a supra-levator exenteration. Table 2 summarizes the tissues typically removed with differing types of pelvic exenteration (See CERV-B 6 of 7). These are highly complex procedures and should be performed in centers with a high level of expertise for exenteration procedures. Primary pelvic exenteration (without prior pelvic radiation) is restricted to the rare case where pelvic radiation is contraindicated or to women who received prior pelvic radiation for another indication and then developed a metachronous, locally advanced cervical carcinoma and further radiation therapy is not feasible.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING

Sentinel Lymph Node Mapping for Cervical Cancer:

- SLN mapping as part of the surgical management of select stage I cervical cancer is considered in gynecologic oncology practices worldwide. While this technique has been used in tumors up to 4 cm in size, the best detection rates and mapping results are in tumors less than 2 cm.9-12 This simple technique utilizes a direct cervical injection with dye or radiocolloid Technetium-99 (99Tc) into the cervix, usually at 2 or 4 points as shown in Figure 1 (below). The SLNs are identified at the time of surgery with direct visualization of colored dye, a fluorescent camera if indocyanine green (ICG) was used, or a gamma probe if 99Tc was used. SLNs following a cervical injection are commonly located medial to the external iliac vessels, ventral to the hypogastric vessels, or in the superior part of the obturator space (Figure 2). SLNs usually undergo ultrastaging by pathologists, which allows for higher detection of micrometastasis that may alter postoperative management.2,13

Figure 1: Options of SLN Cervical Injection Sites†

Figure 2: SLNs (blue, arrow) After Cervical Injection Are Commonly Located Medial to the External Iliac, Ventral to the Hypogastric, or in the Superior Part of the Obturator Space†

†Figures 1 and 2 are reproduced with permission from Memorial Sloan Kettering Cancer Center. © 2013 Memorial Sloan Kettering Cancer Center.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING WHEN SLN MAPPING IS USED

The key to a successful SLN mapping is adherence to the SLN algorithm, which requires the performance of a side-specific nodal dissection in cases of failed mapping and removal of any suspicious or grossly enlarged nodes regardless of mapping (Figure 3).

Figure 3: Surgical/SLN Mapping Algorithm for Early-Stage Cervical Cancer

- Excision of all mapped SLN (submit for ultrastaging if negative H&E)
- Any suspicious nodes must be removed regardless of mapping
- If there is no mapping on a hemi-pelvis, a side-specific LND is performed
- Parametrectomy is performed en bloc with a resection of the primary tumor

H&E: Hematoxylin and eosin staining
LND: Lymphadenectomy
SLN: Sentinel lymph node

††Intracervical injection with dye, 99m technetium, or both.
†††Including interiliac/subaortic nodes.
††††Exceptions made for select cases (see CERV-A 1 of 7).
### PRINCIPLES OF EVALUATION AND SURGICAL STAGING

#### TABLE 1: Resection of Cervical Cancer as Primary Therapy*

<table>
<thead>
<tr>
<th>Indication</th>
<th>Simple/Extrafascial Hysterectomy (Type A)**</th>
<th>Modified Radical Hysterectomy (Type B)**</th>
<th>Radical Hysterectomy (Type C)**</th>
<th>Simple Trachelectomy</th>
<th>Radical Trachelectomy***</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA-1</td>
<td>Stage IA-1 with LVSI and IA-2</td>
<td>Local disease without obvious metastasis, including: Stage IB-1 and 2 Selected Stage IIA</td>
<td>HSIL and stage IA-1</td>
<td>Stage IA-2 and Stage IB-1 if ≤2 cm diameter and squamous histology</td>
<td></td>
</tr>
<tr>
<td>Intent</td>
<td>Curative for microinvasion</td>
<td>Curative for small lesions</td>
<td>Curative for larger lesions</td>
<td>Curative for microinvasion</td>
<td>Curative for select stage IB-1 and IA-2 Fertility preserved</td>
</tr>
<tr>
<td>Uterus</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
</tr>
<tr>
<td>Ovaries</td>
<td>Optional removal</td>
<td>Optional removal</td>
<td>Optional removal</td>
<td>Spared</td>
<td>Spared</td>
</tr>
<tr>
<td>Cervix</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
</tr>
<tr>
<td>Vaginal margin</td>
<td>None</td>
<td>1–2 cm margin</td>
<td>Upper 1/4 to 1/3 of vagina</td>
<td>None</td>
<td>Upper 1/4 to 1/3 of vagina</td>
</tr>
<tr>
<td>Ureters</td>
<td>Not mobilized</td>
<td>Tunneled through broad ligament</td>
<td>Tunneled through broad ligament</td>
<td>Not mobilized</td>
<td>Tunneled through broad ligament</td>
</tr>
<tr>
<td>Cardinal ligaments</td>
<td>Resected at uterine and cervical border</td>
<td>Divided where ureter transits the broad ligament</td>
<td>Divided at pelvic sidewall</td>
<td>Resected at cervical border</td>
<td>Divided at pelvic sidewall</td>
</tr>
<tr>
<td>Uterosacral ligaments</td>
<td>Divided at cervical border</td>
<td>Partially resected</td>
<td>Divided near sacral origin</td>
<td>Divided at cervical border</td>
<td>Divided near sacral origin</td>
</tr>
<tr>
<td>Bladder</td>
<td>Mobilized to base of cervix</td>
<td>Mobilized to upper vagina</td>
<td>Mobilized to middle vagina</td>
<td>Mobilized to peritoneal reflection</td>
<td>Mobilized to peritoneal reflection</td>
</tr>
<tr>
<td>Rectum</td>
<td>Not mobilized</td>
<td>Mobilized below cervix</td>
<td>Mobilized below middle vagina</td>
<td>Mobilized to peritoneal reflection</td>
<td>Mobilized to above peritoneal reflection</td>
</tr>
<tr>
<td>Surgical approach</td>
<td>Laparotomy or laparoscopy</td>
<td>Laparotomy or laparoscopy or robotic laparoscopy</td>
<td>Laparotomy or laparoscopy or robotic laparoscopy</td>
<td>Vaginal</td>
<td>Vaginal or laparotomy or laparoscopy, or robotic laparoscopy</td>
</tr>
</tbody>
</table>


**The Querleu and Morrow surgical classification system describes the degree of resection and nerve preservation for radical hysterectomy in three-dimensional planes and updates the previously used Piver-Rutledge classifications.

***Fertility-sparing radical trachelectomy is most validated for lesions ≤2 cm in diameter. Small cell neuroendocrine histology and adenoma malignum are not considered suitable tumors for this procedure.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### TABLE 2: Resection of Recurrent Cervical Cancer with No Distant Metastasis*

<table>
<thead>
<tr>
<th>Indication</th>
<th>Anterior</th>
<th>Posterior</th>
<th>Total</th>
<th>Posterior</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central pelvic recurrence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary therapy for FIGO stage IVA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Intent</strong></td>
<td>Curative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Uterus, tubes, ovaries</strong></td>
<td>Removed if still present</td>
<td>Removed if still present</td>
<td>Removed if still present</td>
<td>Removed if still present</td>
<td>Removed if still present</td>
</tr>
<tr>
<td><strong>Vagina</strong></td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
</tr>
<tr>
<td><strong>Bladder and urethra</strong></td>
<td>Removed</td>
<td>Preserved</td>
<td>Removed</td>
<td>Preserved</td>
<td>Removed</td>
</tr>
<tr>
<td><strong>Rectum</strong></td>
<td>Preserved</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
</tr>
<tr>
<td><strong>Anal sphincter</strong></td>
<td>Preserved</td>
<td>Removed</td>
<td>Removed</td>
<td>Preserved</td>
<td>Removed</td>
</tr>
<tr>
<td><strong>Reconstruction options</strong></td>
<td>Ileal conduit or Continent conduit</td>
<td>N/A</td>
<td>Ileal conduit or Continent conduit</td>
<td>N/A</td>
<td>Ileal conduit or Continent conduit</td>
</tr>
<tr>
<td><strong>GI system</strong></td>
<td>N/A</td>
<td>End colostomy</td>
<td>End colostomy</td>
<td>End colostomy or anastomosis</td>
<td>End colostomy or anastomosis</td>
</tr>
<tr>
<td><strong>Vagina</strong></td>
<td>Split-thickness skin graft with omental J-flap, or Myocutaneous flap (rectus, gracilis, etc.), or None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING

(References)

External Beam Radiation Therapy (EBRT)

- The use of CT-based treatment planning and conformal blocking is considered the standard of care for EBRT. MRI is the best imaging modality for determining soft tissue and parametrical involvement in patients with advanced tumors. In patients who are not surgically staged, PET imaging is useful to help define the nodal volume of coverage, and may be useful postoperatively to confirm removal of abnormal nodes.

- The volume of EBRT should cover the gross disease (if present), parametria, uterosacral ligaments, sufficient vaginal margin from the gross disease (at least 3 cm), presacral nodes, and other nodal volumes at risk. For patients with negative nodes on surgical or radiologic imaging, the radiation volume should include the entirety of the external iliac, internal iliac, obturator, and presacral nodal basins. For patients deemed at higher risk of lymph node involvement (e.g., bulkier tumors; suspected or confirmed nodes confined to the low true pelvis), the radiation volume should be increased to cover the common iliacs as well. In patients with documented common iliac and/or para-aortic nodal involvement, extended-field pelvic and para-aortic radiotherapy is recommended, up to the level of the renal vessels (or even more cephalad as directed by involved nodal distribution). For patients with lower 1/3 vaginal involvement, the bilateral groins should be covered as well.

- Coverage of microscopic nodal disease requires an EBRT dose of approximately 45 Gy (in conventional fractionation of 1.8–2.0 Gy daily), and highly conformal boosts of an additional 10–20 Gy may be considered for limited volumes of gross unresected adenopathy, with consideration of the dose given by brachytherapy. For the majority of patients who receive EBRT for cervical cancer, concurrent cisplatin-based chemotherapy (either cisplatin alone, or cisplatin + 5-fluorouracil) is given during the time of EBRT.

- Intensity-modulated radiation therapy (IMRT) and similar highly conformal methods of dose delivery may be helpful in minimizing the dose to the bowel and other critical structures in the IMRT post-hysterectomy setting and in treating the para-aortic nodes when necessary. These techniques can also be useful when high doses are required to treat gross disease in regional lymph nodes. However, conformal external beam therapies (such as IMRT or stereotactic body radiation therapy, SBRT) should not be used as routine alternatives to brachytherapy for treatment of central disease in patients with an intact cervix. Very careful attention to detail and reproducibility (including consideration of target and normal tissue definitions, patient and internal organ motion, soft tissue deformation, and rigorous dosimetric and physics quality assurance) is required for proper delivery of IMRT and related highly conformal technologies. Routine image guidance, such as cone-beam CT (CBCT), should be used for defining daily internal soft tissue positioning.

- Concepts regarding the gross target volume (GTV), clinical target volume (CTV), planning target volume (PTV), organs at risk (OARs), and dose-volume histogram (DVH) have been defined for use in conformal radiotherapy, especially for IMRT.

- Stereotactic body radiotherapy (SBRT) is an approach that allows delivery of very high doses of focused external beam radiation in 1–5 fractions and may be applied to isolated metastatic sites, and consideration can be given for limited disease in the reirradiation setting.
**Brachytherapy**

- Brachytherapy is a critical component of definitive therapy for all patients with primary cervical cancer who are not candidates for surgery. This is usually performed using an intracavitary approach, with an intrauterine tandem and vaginal colpostats. Depending on the patient and tumor anatomy, the vaginal component of brachytherapy in patients with an intact cervix may be delivered using ovoids, ring, or cylinder brachytherapy (combined with the intrauterine tandem). MRI immediately preceding brachytherapy may be helpful in delineating residual tumor geometry. When combined with EBRT, brachytherapy is often initiated towards the latter part of treatment, when sufficient primary tumor regression has been noted to permit satisfactory brachytherapy apparatus geometry. In highly selected very early disease (i.e., stage IA2), brachytherapy alone (without EBRT) may be an option.

- In rare cases, patients whose anatomy or tumor geometry renders intracavitary brachytherapy infeasible may be best treated using an interstitial approach; however, such interstitial brachytherapy should only be performed by individuals and at institutions with appropriate experience and expertise and early referral for timely use of their expertise is critical.

- In selected post-hysterectomy patients (especially those with positive or close vaginal mucosal surgical margins), vaginal cylinder brachytherapy may be used as a boost to EBRT. The prescription is typically to the vaginal surface or at 5 mm below the surface. Typical fractionation schemes include 5.5 Gy X 2 fractions dosed at 5 mm or 6 Gy X 3 dosed at the vaginal surface.

- SBRT is not considered an appropriate routine alternative to brachytherapy.

- Point A, representing a paracervical reference point, has been the most widely used, dosing parameter to date. However, limitations of the Point A dosing system include the fact that it does not take into account the three-dimensional shape of tumors, nor individual tumor to normal tissue structure correlations. Typical Point A prescription doses are 5.5 Gy X 5 fractions for early disease and 6 Gy X 5 for large tumors or those demonstrating a poor response. There is evidence that image-guided brachytherapy improves outcomes and decreases toxicity. MRI gives the best soft tissue imaging for residual disease and while it is best to have an MRI with the instruments in place, an MRI prior to brachytherapy can help guide therapy. In the absence of MRI, CT can be used but is inferior for determination of residual disease and contouring is less accurate. The goals of care would include an equivalent dose at 2 Gy (EQD2) to the high risk CTV (HR-CTV) of ≥80 Gy, however with large disease or poor response dose goals should be ≥87 Gy. Normal tissues should be limited according to published guidelines with 2cc rectal dose ≤65-75 Gy, sigmoid 2 cc dose ≤70-75 Gy and 2 cc bladder dose ≤80-90 Gy. If those parameters cannot be achieved supplemental dosing with interstitial needles should be considered.\(^4,5\)

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**PRINCIPLES OF RADIATION THERAPY**

**Radiation Dosing Considerations**

- Image guided brachytherapy is encouraged with prescribing to a HR-CTV. The most common historical dosing parameters for brachytherapy use a system that includes specifying the dose at point A and incorporates specific guidelines for “radioactive source loading and distribution of activity” within the uterus and vagina, based on anatomic considerations. Doses are also calculated at standardized point B and bladder and rectal points. Current efforts at 3-D image-guided brachytherapy seek to optimize implant dose coverage of the tumor, while potentially reducing the dose to adjacent bladder, rectum, and bowel structures. Nonetheless, the weight of experience and tumor control results and the majority of continuing clinical practice have been based on the point A dosing system. Attempts to improve dosing with image-guided brachytherapy should take care not to underdose tumors relative to the point A system dose recommendations.

- The point A dose recommendations provided in the NCCN Guidelines are based on traditional, and widely validated, dose fractionation and brachytherapy at low dose rates (LDRs). In these provided dose recommendations, for EBRT, the dose is delivered at 1.8 to 2.0 Gy per daily fraction. For brachytherapy, the dose at point A assumes an LDR delivery of 40 to 70 cGy/h. Clinicians using HDR brachytherapy would depend on the linear-quadratic model equation to convert nominal HDR dose to point A to a biologically equivalent LDR dose to point A. Multiple brachytherapy schemes have been used when combined with EBRT. However, one of the more common HDR approaches is 5 insertions with tandem and colpostats, each delivering 6 Gy nominal dose to point A. This scheme results in a nominal HDR point A dose of 30 Gy in 5 fractions, which is generally accepted to be the equivalent to 40 Gy to point A (tumor surrogate dose) using LDR brachytherapy. 28 Gy in four fractions, which is well studied in European trials, is also a reasonable choice for intracavitary dosing to the high risk CTV. Smaller tumors or rapidly responding tumors may be adequately treated with lower doses.
Definitive Radiation Therapy for an Intact Cervix

• In patients with an intact cervix (ie, those who do not have surgery), the primary tumor and regional lymphatics at risk are typically treated with definitive EBRT to a dose of approximately 45 Gy (40–50 Gy). The volume of the EBRT would depend on the nodal status as determined surgically or radiographically (as previously described). The primary cervical tumor is then boosted, using brachytherapy, with an additional 30 to 40 Gy to point A (in LDR equivalent dose), for a total point A dose (as recommended in the guidelines) of 80 Gy for small-volume cervical tumors or ≥85 Gy for larger-volume cervical tumors. Grossly involved unresected nodes may be evaluated for boosting with an additional 10 to 15 Gy of highly conformal (and reduced volume) EBRT. With higher doses, especially of EBRT, care must be taken to exclude or severely limit the volume of normal tissue included in the high-dose region(s) (see Discussion).

Posthysterectomy Adjuvant Radiation Therapy

• Following primary hysterectomy, the presence of one or more pathologic risk factors may warrant the use of adjuvant radiotherapy. At a minimum, the following should be covered: upper 3 to 4 cm of the vaginal cuff, the parametria, and immediately adjacent nodal basins (such as the external and internal iliacs). For documented nodal metastasis, the superior border of the radiation field should be appropriately increased (as previously described). A dose of 45 to 50 Gy in standard fractionation is generally recommended. Grossly involved unresected nodes may be evaluated for boosting with an additional 10 to 20 Gy of highly conformal (and reduced volume) EBRT. With higher doses, especially of EBRT, care must be taken to exclude or severely limit the volume of normal tissue included in the high-dose region(s) (see Discussion).

Intraoperative Radiation Therapy

• IORT is a specialized technique that delivers a single, highly focused dose of radiation to an at-risk tumor bed or isolated unresectable residual disease during an open surgical procedure. It is particularly useful in patients with recurrent disease within a previously radiated volume. During IORT, overlying normal tissue (such as bowel or other viscera) can be manually displaced from the region at risk. IORT is typically delivered with electrons using preformed applicators of variable sizes matched to the surgically defined region at risk, which further constrains the area and depth of radiation exposure to avoid surrounding normal structures.
PRINCIPLES OF RADIATION THERAPY

(References)


SEDILS CRITERIA FOR EXTERNAL PELVIC RADIATION AFTER RADICAL HYSTERECTOMY IN NODE-NEGATIVE, MARGIN-NEGATIVE, PARAMETRIA-NEGATIVE CASES¹-⁴

<table>
<thead>
<tr>
<th>LVSI</th>
<th>Stromal Invasion</th>
<th>Tumor Size (cm) (Determined by clinical palpation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>Deep 1/3</td>
<td>Any</td>
</tr>
<tr>
<td>+</td>
<td>Middle 1/3</td>
<td>≥2</td>
</tr>
<tr>
<td>+</td>
<td>Superficial 1/3</td>
<td>≥5</td>
</tr>
<tr>
<td>-</td>
<td>Middle or Deep 1/3</td>
<td>≥4</td>
</tr>
</tbody>
</table>

LVSI: Lymphovascular space invasion

⁴Risk factors may not be limited to the Sedlis Criteria.
**SYSTEMIC THERAPY REGIMENS FOR CERVICAL CANCER†**
(Strongly consider clinical trial)

**Chemoradiation (preferred regimens)**
- Cisplatin
- Cisplatin/fluorouracil

**First-line combination therapy††,** *
- Cisplatin/paclitaxel/bevacizumab
  (category 1)
- Cisplatin/paclitaxel (category 1)²,³
- Topotecan/paclitaxel/bevacizumab
  (category 1)
- Carboplatin/paclitaxel⁴,⁵
  (Category 1 for patients who have received
  prior cisplatin therapy)
- Carboplatin/paclitaxel/bevacizumab
- Cisplatin/topotecan⁶
- Topotecan/paclitaxel¹
- Cisplatin/gemcitabine (category 3)⁷

**Possible first-line single-agent therapy** *
- Cisplatin (preferred as a single agent)³
- Carboplatin⁸
- Paclitaxel⁹,¹⁰

**Second-line therapy** **
(All agents listed here are category 2B)
- Bevacizumab
- Albumin-bound paclitaxel
- Docetaxel
- 5-FU (5-fluorouracil)
- Gemcitabine
- Ifosfamide
- Irinotecan
- Mitomycin
- Pemetrexed
- Topotecan
- Vinorelbine
- Pembrolizumab (for MSI-H/dMMR tumors)

†Cisplatin, carboplatin, docetaxel, and paclitaxel may cause drug reactions. (See NCCN Guidelines for Ovarian Cancer—Management of Drug Reactions [OV-C]).
††Cost and toxicity should be carefully considered when selecting an appropriate regimen for treatment.
*These agents can be used as second-line therapy if not used previously.
**References for second-line therapy are provided in the Discussion.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC CERVICAL CANCER

(References)


# NCCN Guidelines Version 1.2018 Staging Cervical Cancer

## Staging-Cervical Cancer

**Table 1**

AJCC Tumor-Node-Metastases (TNM) and International Federation of Gynecology and Obstetrics (FIGO) Surgical Staging Systems for Carcinoma of the Uterine Cervix

### Definition of Primary Tumor (T)

<table>
<thead>
<tr>
<th>T Category</th>
<th>FIGO Stage</th>
<th>T Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td></td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>I</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>T1</td>
<td>IB</td>
<td>Cervical carcinoma confined to the uterus (extension to corpus should be disregarded)</td>
</tr>
<tr>
<td>T1a</td>
<td>IA</td>
<td>Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification</td>
</tr>
<tr>
<td>T1a1</td>
<td>IA1</td>
<td>Measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread</td>
</tr>
<tr>
<td>T1a2</td>
<td>IA2</td>
<td>Measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less</td>
</tr>
<tr>
<td>T1b</td>
<td>IB</td>
<td>Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. Includes all macroscopically visible lesions, even those with superficial invasion.</td>
</tr>
<tr>
<td>T1b1</td>
<td>IB1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1b2</td>
<td>IB2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2</td>
<td>II</td>
<td>Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of the vagina</td>
</tr>
<tr>
<td>T2a</td>
<td>IIA</td>
<td>Tumor without parametrial invasion</td>
</tr>
<tr>
<td>T2a1</td>
<td>IIA1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T2a2</td>
<td>IIA2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2b</td>
<td>IIB</td>
<td>Tumor with parametrial invasion</td>
</tr>
<tr>
<td>T3</td>
<td>III</td>
<td>Tumor extending to the pelvic sidewall* and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney</td>
</tr>
<tr>
<td>T3a</td>
<td>IIIA</td>
<td>Tumor involving the lower third of the vagina but not extending to the pelvic wall</td>
</tr>
<tr>
<td>T3b</td>
<td>IIIB</td>
<td>Tumor extending to the pelvic wall and/or causing hydronephrosis or nonfunctioning kidney</td>
</tr>
<tr>
<td>T4</td>
<td>IVA</td>
<td>Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4)</td>
</tr>
</tbody>
</table>

*The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. On rectal examination, there is no cancer-free space between the tumor and pelvic sidewall.*

The AJCC 8th Edition Cancer Staging System will be implemented on January 1, 2018. For the AJCC 7th Edition Staging Manual, visit [www.springer.com](http://www.springer.com). Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media. (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.


Version 1.2018, 10/25/17 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Staging-Cervical Cancer

Table 1 continued

Definition of Regional Lymph Node (N)

<table>
<thead>
<tr>
<th>N Category</th>
<th>FIGO Stage</th>
<th>N Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td></td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td></td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N0(i+)</td>
<td></td>
<td>Isolated tumor cells in regional lymph node(s) no greater than 0.2 mm</td>
</tr>
<tr>
<td>N1</td>
<td></td>
<td>Regional lymph node metastasis</td>
</tr>
</tbody>
</table>

Definition of Metastasis (M)

<table>
<thead>
<tr>
<th>M Category</th>
<th>FIGO Stage</th>
<th>M Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td></td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>IVB</td>
<td>Distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone)</td>
</tr>
</tbody>
</table>

Histologic Grade (G)

<table>
<thead>
<tr>
<th>G</th>
<th>G Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>GX</td>
<td>Grade cannot be assessed</td>
</tr>
<tr>
<td>G1</td>
<td>Well differentiated</td>
</tr>
<tr>
<td>G2</td>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>G3</td>
<td>Poorly differentiated or undifferentiated</td>
</tr>
</tbody>
</table>
Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 10/10/16

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ................................................................. MS-2

Literature Search Criteria and Guidelines Update Methodology ........ MS-2

Diagnosis and Workup .................................................. MS-3

Principles of Staging and Surgery ..................................... MS-4

Clinical Staging ................................................................ MS-4

Surgical Staging ........................................................... MS-4

Primary Treatment ......................................................... MS-7

Important Phase III Clinical Trials Underpinning Treatment

Recommendations ......................................................... MS-7

Early-Stage Disease ..................................................... MS-8

Advanced Disease ....................................................... MS-10

Metastatic Disease ....................................................... MS-11

Adjuvant Treatment ..................................................... MS-12

Surveillance ............................................................... MS-13

Therapy for Relapse ...................................................... MS-14

Locoregional Therapy .................................................. MS-14

Therapy for Metastatic Disease ....................................... MS-15

Incidental Cervical Cancer ............................................. MS-18

Radiation Therapy ....................................................... MS-19

Radiation Treatment Planning ....................................... MS-19

Normal Tissue Considerations ....................................... MS-20

Cervical Cancer and Pregnancy ...................................... MS-21

Summary .................................................................... MS-21

References .................................................................... MS-23
Overview
An estimated 12,990 new cases of carcinoma of the uterine cervix (ie, cervical cancer) will be diagnosed in the United States in 2016, and 4120 people will die of the disease.¹ Cervical cancer rates are decreasing among women in the United States, although incidence remains high among Hispanic/Latino, Black, and Asian women.²⁻⁵ However, cervical cancer is a major world health problem for women. The global yearly incidence of cervical cancer in 2012 was 528,000; the annual death rate was 266,000.⁶ It is the fourth most common cancer in women worldwide,⁷⁻⁸ with 85% of cases occurring in developing countries, where cervical cancer is a leading cause of cancer death in women.⁶⁻⁹ Persistent human papillomavirus (HPV) infection is the most important factor in the development of cervical cancer.¹⁰⁻¹¹ The incidence of cervical cancer appears to be related to the prevalence of HPV in the population. In countries with a high incidence of cervical cancer, the prevalence of chronic HPV is approximately 10% to 20%, whereas the prevalence in low-incidence countries is 5% to 10%.⁷ Immunization against HPV prevents infection with the types of HPV against which the vaccine is designed and, thus, is expected to prevent specific HPV cancer in women.¹²⁻¹⁶ Other epidemiologic risk factors associated with cervical cancer are a history of smoking, parity, oral contraceptive use, early age of onset of coitus, larger number of sexual partners, history of sexually transmitted disease, certain autoimmune diseases, and chronic immunosuppression.¹⁷⁻¹⁸ Smoking cessation should be advised in current smokers, and former smokers should continue to avoid smoking (See the NCCN Guidelines for Smoking Cessation and http://smokefree.gov/).

Squamous cell carcinomas account for approximately 80% of all cervical cancers and adenocarcinoma accounts for approximately 20%. In developed countries, the substantial decline in incidence and mortality of squamous cell carcinoma of the cervix is presumed to be the result of effective screening, although racial, ethnic, and geographic disparities exist.²⁻³,¹⁹⁻²⁰ However, adenocarcinoma of the cervix has increased over the past 3 decades, probably because cervical cytologic screening methods are less effective for adenocarcinoma.²¹⁻²⁴ Screening methods using HPV testing may increase detection of adenocarcinoma. Vaccination with HPV vaccines may also decrease the incidence of both squamous cell carcinoma and adenocarcinoma.²³,²⁵

By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. "Many exceptions to the rule" were discussed among the members of the cervical cancer panel during the process of developing these guidelines.

Literature Search Criteria and Guidelines Update Methodology
Prior to the update of this version of the NCCN Guidelines® for Cervical Cancer, an electronic search of the PubMed database was performed to obtain key literature in cervical cancer published between 04/01/2015 and 04/01/2016, using the following search terms: cervical cancer or cervical carcinoma or carcinoma of the cervix. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial,
Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 71 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Diagnosis and Workup

These NCCN Guidelines discuss squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. Neuroendocrine carcinoma, small cell tumors, glassy-cell carcinomas, sarcomas, and other histologic types are not within the scope of these guidelines.

Currently, the International Federation of Gynecology and Obstetrics (FIGO) evaluation procedures for staging are limited to colposcopy, biopsy, conization of the cervix, cystoscopy, and proctosigmoidoscopy. More complex radiologic and surgical staging procedures are not addressed in the FIGO classification. In the United States, however, CT, MRI, combined PET/CT, and surgical staging are often used to guide treatment options and design.26-30

The earliest stages of cervical carcinoma may be asymptomatic or associated with a watery vaginal discharge and postcoital bleeding or intermittent spotting. Often these early symptoms are not recognized by the patient. Because of the accessibility of the uterine cervix, cervical cytology or Papanicolaou (Pap) smears and cervical biopsies can usually result in an accurate diagnosis. Cone biopsy (ie, conization) is recommended if the cervical biopsy is inadequate to define invasiveness or if accurate assessment of microinvasive disease is required. However, cervical cytologic screening methods are less useful for diagnosing adenocarcinoma, because adenocarcinoma in situ affects areas of the cervix that are harder to sample (ie, endocervical canal).5,24 The College of American Pathologists (CAP) protocol for cervical carcinoma is a useful guide (http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Cervix_12protocol.pdf). This CAP protocol was revised in June 2012 and reflects recent updates in the AJCC/FIGO staging (ie, AJCC Cancer Staging Manual, 7th edition).

Workup for these patients with suspicious symptoms includes history and physical examination, complete blood count (CBC) (including platelets), and liver and renal function tests. Recommended radiologic imaging includes chest radiograph, CT, or combined PET/CT, and MRI as indicated (eg, to rule out disease high in the endocervix).27,31 For detailed imaging recommendations by stage and planned treatment approach, see Principles of Imaging in the NCCN Guidelines for Cervical Cancer). Cystoscopy and proctoscopy are only recommended if bladder or rectal extension is suspected. The panel had major disagreement whether physicians should consider HIV (human immunodeficiency virus) testing as part of a patient’s initial workup; this recommendation is included as a category 3.
Principles of Staging and Surgery

Clinical Staging

Because noninvasive radiographic imaging may not be routinely available in low-resource countries, the FIGO system limits the imaging to chest radiography, intravenous pyelography, and barium enema. The staging of carcinoma of the cervix is largely a clinical evaluation. Although surgical staging is more accurate than clinical staging, surgical staging often cannot be performed in low-resource countries. The panel currently uses the 2009 FIGO definitions and staging system (see Table 1). FIGO directly aligns with AJCC staging with the exception of stage 0, which does not exist in the FIGO system. Additionally, regional nodal metastasis is not included in the FIGO staging criteria. With the 2009 FIGO staging, stage IIA is now subdivided into stage IIA1 (tumor size ≤4 cm) and stage IIA2 (tumor size >4 cm), which is the only change from the previous 1994 FIGO staging system.

Importantly, lymphovascular space invasion (LVSI) does not alter the FIGO classification. FIGO did not include LVSI because pathologists do not always agree on whether LVSI is present in tissue samples. Some panel members believe that patients with stage IA1 who have extensive LVSI should be treated using stage IB1 guidelines.

The use of MRI, CT, or combined PET/CT scans may aid in treatment planning, but it is not accepted for formal staging purposes. In addition, FIGO has always maintained that staging is intended for comparison purposes only and not as a guide for therapy. As a result, the panel uses the FIGO definitions as the stratification system for these guidelines, although the findings on imaging studies (ie, CT, MRI, and PET/CT) are used to guide treatment options and design. MRI is useful to delineate disease extent and to guide decisions regarding fertility-sparing versus non-fertility-sparing treatment approaches, while PET/CT may be useful to detect and/or rule out metastasis.

Surgical Staging

Conservative/Fertility-Sparing Approaches

Fertility-sparing approaches may be considered in highly selected patients who have been thoroughly counseled regarding disease risk as well as prenatal and perinatal issues.

Microinvasive disease (FIGO stage IA-1 with no LVSI) is associated with an extremely low incidence of lymphatic metastasis, and conservative treatment with conization is an option (category 2A) for individuals with no evidence of LVSI. In stage IA1 individuals with evidence of LVSI, a reasonable conservative approach is conization (with negative margins) in addition to SLN mapping algorithm or pelvic lymphadenectomy.

The goal of conization is en bloc removal of the ectocervix and endocervical canal; the shape of the cone can be tailored to the size, type, and location of the lesion (ie, narrow, long cone in cases of suspected invasive adenocarcinoma). The panel recommends cold knife conization as the preferred approach to conization. However, LEEP (loop electrosurgical excision procedure) is acceptable as long as adequate margins, proper orientation, and a non-fragmented specimen without electrosurgical artifact can be obtained. Endocervical curettage may be added as clinically indicated.

Select patients with stage IA-2 or IB1 cervical cancer, especially for those with tumors of less than 2 cm in diameter, may be eligible for conservative surgery. Radical trachelectomy may offer a reasonable fertility-sparing treatment option for patients with stage IA-2 or IB-1 cervical cancer with lesions that are less than or equal to 2 cm in size.
In a radical trachelectomy, the cervix, vaginal margins, and supporting ligaments are removed while leaving the main body and fundus of the uterus intact. Laparoscopic pelvic lymphadenectomy accompanies the procedure and can be performed with or without SLN mapping (see Lymph Node Mapping and Dissection below). Due to their aggressive nature, tumors of small cell neuroendocrine histology are considered inappropriate for radical trachelectomy. Trachelectomy is also inappropriate for treating gastric type cervical adenocarcinoma and adenoma malignum (minimal deviation adenocarcinoma) due to their diagnostic challenges and potentially aggressive nature.

Vaginal radical trachelectomy (VRT) may be used for carefully selected patients with lesions of 2 cm diameter or less. Abdominal radical trachelectomy (ART) provides a broader resection of the parametria than the vaginal approach and is commonly used in stage IB1 lesions. Multiple case series have evaluated safety and outcomes with vaginal vs. abdominal approaches to radical trachelectomy including systematic reviews on VRT and ART. A limited number of studies have specifically examined this approach in patients with larger stage IB1 tumors between 2 cm and 4 cm in diameter and reported safe oncologic outcomes, but as expected, more patients in this subgroup will require adjuvant therapy that may reduce fertility.

Studies that examined pregnancy in women who underwent radical trachelectomy have provided differing success rates. One case series of 125 patients with cervical cancer who underwent VRT reported 106 pregnancies among 58 women. In a systematic review of 413 women who underwent ART, 113 women attempted pregnancy and 67 (59%) successfully conceived. However, miscarriage and pre-term labor rates were elevated among women who underwent radical trachelectomy.

Non-Fertility-Sparing Approaches

The Querleu and Morrow surgical classification system describes the degree of resection and nerve preservation for radical hysterectomy in three-dimensional planes and updates the previously used Piver-Rutledge classifications. Approaches to hysterectomy include simple/extrafascial hysterectomy (Type A), modified radical hysterectomy (Type B), and radical hysterectomy (Type C).

For patients with IA-1 disease, cone excision, simple/extrafascial hysterectomy, and modified radical hysterectomy are options. Radical hysterectomy with bilateral pelvic lymph node dissection (with or without SLN mapping) is the preferred treatment approach for patients with FIGO stage IA-2 through IIA1 cervical cancers. Radical hysterectomy is preferred over simple hysterectomy due to its wider paracervix margin of resection that also includes aspects of the cardinal and uterosacral ligaments, upper vagina, pelvic nodes, and at times, para-aortic nodes. In the United States, definitive chemoradiation is typically preferred over radical surgery for select patients with bulky FIGO IB2 lesions and the vast majority of FIGO stage IIA2 or greater cervical cancers. Abroad, select FIGO IB2-IIB cases may be treated with radical hysterectomy or neoadjuvant chemotherapy followed by radical hysterectomy.

For recurrent or persistent cervical cancers that are confined to the central pelvis (ie, no distant metastasis), pelvic exenteration may be a potentially curative surgical option. Discussion of the various approaches to pelvic exenteration are offered by Chi and colleagues, and in the GOG Surgical Manual.
Lymph Node Mapping and Dissection

Sentinel Lymph Node Mapping
Recent data suggest that SLN biopsy may be useful for decreasing the need for pelvic lymphadenectomy in patients with early-stage cervical cancer.\(^90\)

Prospective studies generally support the feasibility of SLN detection in patients with early-stage cervical cancer and suggest that extensive pelvic lymph node dissection may be safely avoided in a significant proportion of early-stage cases.\(^89\)\(^-\)\(^100\)

Meta-analyses of pooled data from SLN mapping studies have generated SLN detection rates of 89-92% and sensitivity of 89% to 90%.\(^101\)\(^,\)\(^102\) Factors determined to be important for detection included laparoscopy, dual blue dye/ radiocolloid tracer approaches, and pathologic assessment using immunohistochemistry. However, based on a recent metaanalysis, indocyanine green tracer appears to provide similar overall and bilateral detection rates to the standard dual blue dye/ technetium-99 approach.\(^103\)

However, study data also highlight limited sensitivity of this approach and potential to miss SLN micrometastases and isolated tumor cells using intraoperative assessment (ie, frozen section or imprint cytology).\(^92\)\(^,\)\(^96\)\(^,\)\(^98\) The sensitivity of this approach appears to be better in patients with tumors equal to or less than 2 cm in diameter.\(^89\)\(^,\)\(^91\)\(^,\)\(^93\)\(^,\)\(^104\)

Ultrastaging of detected SLNs has been shown to provide enhanced detection of micrometastases.\(^94\)\(^,\)\(^95\)

The SENTICOL longitudinal study demonstrated the utility of SLN mapping to uncover unusual lymph drainage patterns.\(^93\)\(^,\)\(^105\) It also highlighted limited agreement between lymphoscintigraphy and intraoperative SLN mapping.\(^105\)

Bilateral SLN detection and biopsy provided a more reliable assessment of sentinel nodal metastases and led to fewer false negatives than unilateral SLN biopsy.\(^90\) Generally, research supports ipsilateral lymphadenectomy if no sentinel nodes are detected on a given side of the pelvis as outlined in the SLN mapping algorithm.\(^89\)\(^,\)\(^90\)\(^,\)\(^106\)

Based on these collective data, the panel recommends consideration of SLN mapping algorithm and emphasizes that best detection and mapping results are in tumors of less than 2 cm diameter. Adherence to the SLN mapping algorithm is important; surgeons should perform side-specific nodal dissection in any cases of failed mapping and remove all suspicious or grossly enlarged nodes regardless of SLN mapping.\(^90\)

Para-Aortic Lymph Node Assessment
Studies of the incidence and distribution of lymph node metastases in women with stage IB to IIB cervical cancers suggest that para-aortic lymph node involvement is closely tied to the presence of pelvic lymph node metastases, larger primary tumor size (>2 cm), and metastasis to the common iliac nodes.\(^107\)\(^,\)\(^108\)

Analysis of outcomes data from 555 women who participated in Gynecologic Oncology Group (GOG) trials (GOG 85, GOG 120, and GOG 165) revealed a more positive prognosis for patients who underwent surgical exclusion of para-aortic lymph node involvement versus those who underwent radiographic determination of para-aortic node involvement.\(^29\) One study examined the efficacy of extending the radiation therapy (RT) field to the para-aortic region in patients with para-aortic lymph node involvement, and showed therapeutic benefit especially in patients with small-volume nodal disease.\(^109\) A randomized controlled trial examining surgical versus radiologic staging and treatment of para-aortic lymph node involvement is ongoing.\(^110\)
The panel includes para-aortic lymph node sampling (category 2B) as an option during pelvic lymph node dissection.

**Minimally Invasive Surgical Approaches**

Panel members discussed whether laparoscopic and robotic approaches should be recommended for staging and treatment. These techniques are being used more frequently and have been found to be therapeutically feasible and beneficial when performed by appropriately-trained and experienced surgeons. Potential advantages associated with laparoscopic and robotic approaches include decreased hospital stay and more rapid patient recovery.

Laparoscopic staging, lymphadenectomies, and radical hysterecromies can be performed satisfactorily and are used routinely in selected patients in several NCCN Member Institutions. Data suggest that oncologic outcomes following laparoscopic radical hysterectomy are comparable to abdominal approaches after 3 to 6 years of follow-up.

Robotic radical hysterectomy (which is another minimally invasive surgical technique) is currently being performed for patients with early-stage cervical cancer. A recent systematic review and meta-analysis of data from 26 studies found that laparoscopic and robotic radical hysterectomy approaches appeared to provide equivalent intraoperative and short-term postoperative outcomes. Robotic radical hysterectomy has been associated with less blood loss, shorter hospital stay, and wound-related complications compared with open abdominal approaches. Additional recent studies have shown comparable oncologic outcomes (disease recurrence and survival rates) for abdominal and robotic radical hysterectomy after 3 to 5 years followup.

The ongoing randomized phase III LACC trial (NCT00614211) seeks to provide definitive comparison of outcomes data in more than 700 patients undergoing open radical abdominal hysterectomy, or total laparoscopic radical hysterectomy/total robotic radical hysterectomy.

**Primary Treatment**

The primary treatment of early-stage cervical cancer is either surgery or RT. Surgery is typically reserved for early-stage disease, fertility-preservation, and smaller lesions, such as stage IA, IB1, and selected IIA1. Chemoradiation can also be used for patients who are not candidates for hysterectomy. Although few studies have assessed treatment specifically for adenocarcinomas, they are typically treated in a similar manner to squamous cell carcinomas.

Pelvic RT or chemoradiation will invariably lead to ovarian failure in premenopausal women. To preserve intrinsic hormonal function, ovarian transposition may be considered before pelvic RT for select women younger than 45 years of age with squamous cell cancers.

**Important Phase III Clinical Trials Underpinning Treatment Recommendations**

A randomized Italian study compared RT alone versus radical hysterectomy and lymph node dissection in patients with clinical early-stage disease (stage IB–IIA). Adjuvant RT was given to those with parametrial extension, less than 3 cm of uninvolved cervical stroma, positive margins, or positive nodes. Identical outcomes were noted for patients treated with radiation versus surgery, with (or without) postoperative radiation, but higher complication rates were noted for the combined modality approach.
Concurrent chemoradiation, using cisplatin-based chemotherapy (either cisplatin alone or cisplatin/5-FU), is the treatment of choice for stages IB2, II, III, and IVA disease based on the results of 5 randomized clinical trials (see Table 2). These 5 trials have shown that the use of concurrent chemoradiation results in a 30% to 50% decrease in the risk of death compared with RT alone. Although the optimal concurrent chemotherapy regimen to use with RT requires further investigation, these 5 trials clearly established a role for concurrent cisplatin-based chemoradiation. Based on these data, the NCI issued an alert stating that strong consideration should be given to using chemoradiation instead of RT alone for invasive cervical cancer. Long-term follow-up of 3 of these trials has confirmed that concurrent cisplatin-based chemoradiation improves progression-free survival (PFS) and overall survival when compared with RT with (or without) hydroxyurea. A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; \( P < .001 \)). A large, population-based registry analysis in Canada (n=4069) confirmed that chemoradiotherapy improved outcomes when compared with RT alone.

Although chemoradiation is tolerated, acute and long-term side effects have been reported. Some oncologists prefer concurrent single-agent cisplatin chemoradiation over cisplatin plus 5-FU chemoradiation, because the latter may be more toxic. Concurrent carboplatin or nonplatinum chemoradiation regimens are options for patients who may not tolerate cisplatin-containing chemoradiation. Note that when concurrent chemoradiation is used, the chemotherapy is typically given when the external-beam pelvic radiation is administered. The panel believes that using “systemic consolidation” (ie, adding chemotherapy after chemoradiation) should only be used in clinical trials (eg, OUTBACK [ANZGOG-0902/GOG 274, NCT01414608] and RTOG 724 [NCT00980954]).

**Early-Stage Disease**

After careful clinical evaluation and staging, the primary treatment of early-stage cervical cancer is either surgery or RT. The treatment schema is stratified using the FIGO staging system (see Table 1). A new fertility-sparing algorithm was added in 2012 for select patients with stage IA and IB1 disease (see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). Fertility-sparing surgery is generally not recommended for patients with small cell neuroendocrine tumors, gastric type adenocarcinoma, or adenoma malignum (minimal deviation adenocarcinoma) because of high-risk nature and a paucity of data.

**Stage IA1 Disease**

Recommended options for stage IA1 disease depend on the results of cone biopsy and whether patients 1) want to preserve their fertility; 2) are medically operable; or 3) have LVSI [see Primary Treatment (Fertility Sparing) and Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer]. The extent of the lymph node dissection depends on whether pelvic nodal disease and/or LVSI are present and the size of the tumors. SLN mapping can be considered.

**Fertility-Sparing**

For patients who desire fertility preservation, cone biopsy with or without pelvic lymph node dissection is recommended. The goal of cone biopsy is margins that are negative for invasive disease and high-grade squamous intraepithelial lesion (HSIL). For patients with negative margins after cone biopsy and no findings of LVSI, observation may be an option if fertility preservation is desired.
For patients with positive margins after cone biopsy, options include repeat cone biopsy to better evaluate depth of invasion or a radical trachelectomy. In studies of patients who had positive margins after conization, predictors of residual disease included positive endocervical curettage, combined endocervical margin and endocervical curettage, and volume of disease.160-162

For patients with stage IA-1 disease with LVSI, conization (with negative margins) plus laparoscopic pelvic SLN mapping/lymphadenectomy is a reasonable strategy. In addition, these patients may also be treated with a radical trachelectomy and SLN mapping/pelvic lymph node dissection with (or without) para-aortic lymph node sampling (category 2B for elective para-aortic lymph node sampling) [see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer].73,163-166

After childbearing is complete, hysterectomy can be considered for patients who have had either radical trachelectomy or a cone biopsy for early-stage disease if they have chronic, persistent HPV infection, they have persistent abnormal Pap tests, or they desire this surgery.

For young (<45 years) premenopausal women with early-stage squamous cell carcinoma who opt for ovarian preservation (ie, hysterectomy only), the rate of ovarian metastases is low.167,168

**Stage IA2 Disease**

Recommendations for stage IA2 depend upon whether a patient wishes to preserve her fertility and if the disease is medically operable.

**Fertility-Sparing**

For patients who wish to preserve their fertility, radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling (category 2B for para-aortic node sampling) is recommended. SLN mapping can also be considered. Cone biopsy followed by observation is another option if the margins are negative and pelvic lymph node dissection is negative.

**Non–Fertility-Sparing**

For medically and technically operable patients who do not desire fertility preservation, extrafascial (ie, simple) hysterectomy is commonly recommended for patients without LVSI and with either negative margins after cone biopsy or with positive margins for dysplasia. For patients with positive margins for carcinoma, modified radical hysterectomy is recommended with SLN mapping/pelvic lymph node dissection (category 2B for node dissection). SLN mapping can be considered. Physicians can also consider repeat cone biopsy to better evaluate depth of invasion. If LVSI is present, then modified radical hysterectomy with SLN mapping/lymph node dissection is recommended (category 2B for elective para-aortic lymph node sampling only). Para-aortic node dissection is indicated for patients with known or suspected pelvic nodal disease. For patients with negative margins after cone biopsy, observation is recommended for those who are medically inoperable or those who refuse surgery.
Pelvic external beam radiation (EBRT) with brachytherapy (traditionally 70-80 Gy to total point A dose) is a treatment option for patients who are medically inoperable or who refuse surgery. These doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose-rate (40–70 cGy/h) brachytherapy equivalents. Treatment should be modified based on normal tissue tolerance, fractionation, and size of target volume or on biologic equivalence calculations when using high-dose-rate brachytherapy (see also the Radiation Therapy section in this Discussion).

Stage IB and IIA Disease
Depending on their stage and disease bulk, patients with stage IB or IIA tumors can be treated with surgery, RT, or concurrent chemoradiation. Fertility-sparing surgery is only recommended for select patients with stage IB1 disease (see next section). A combined PET/CT scan can be performed to rule out extrapelvic disease before deciding how to treat these patients. The GOG considers that surgical staging is an option for patients with advanced cervical cancer. Radiologic imaging is recommended for assessing stage IB2 and IIA2 tumors (see Principles of Imaging in the NCCN Guidelines for Cervical Cancer).

Stage IB1: Fertility-Sparing
For patients who desire fertility preservation, radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling is an option for stage IB1 disease, but typically only for tumors 2 cm or less [see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer]. SLN mapping can also be considered. Tumors that are 2 to 4 cm have to be carefully selected for a fertility sparing approach as many of these patients may require postoperative adjuvant therapy due to pathologic risk factors (eg, Sedlis criteria or positive nodes). However, some surgeons suggest that a 2-cm cutoff may be used for vaginal trachelectomy, whereas a 4-cm cutoff may be used for abdominal (eg, laparotomy, laparoscopic, robotic) trachelectomy. In one study, oncologic outcomes were similar after 4 years when comparing radical trachelectomy with radical hysterectomy for patients with stage IB1 cervical carcinoma. Stage IB1 small cell neuroendocrine histology, gastric type adenocarcinoma, and adenoma malignum are not considered suitable for fertility-sparing surgery.

Stage IB and IIA: Non-Fertility-Sparing
Primary surgery consists of radical hysterectomy plus bilateral pelvic lymph node dissection with (or without) para-aortic lymph node sampling (category 1 for primary surgery). SLN mapping can also be considered for stages IB1 and IIA1. Panel members feel that surgery is the most appropriate option for patients with stage IB1 or IIA1 disease, whereas concurrent chemoradiation is the most appropriate option for those with stage IB2 or IIA2 disease based on randomized trials. Thus, the surgical option is category 1 for patients with stage IB1 or IIA1 disease; however, surgery is category 2B for those with stage IB2 or IIA2 disease. Para-aortic node dissection may be performed for patients with larger tumors and suspected or known pelvic nodal disease. Some panel members feel that a pelvic lymph node dissection should be performed first and if negative, then the radical hysterectomy should be performed. If the lymph nodes are positive, then the hysterectomy should be abandoned; these patients should undergo chemoradiation. For patients with stage IB or IIA tumors (including those who are not candidates for hysterectomy), another option is combined pelvic EBRT and brachytherapy with (or without) concurrent cisplatin-containing chemotherapy [see Primary Treatment (Non-Fertility Sparing) in the NCCN Guidelines for Cervical Cancer]. Although concurrent chemoradiation has been proven effective in the
definitive treatment of more advanced-stage disease, this approach has not been specifically studied in patients with stage IB1 or IIA1 disease. Careful consideration of the risk/benefit ratio should be undertaken in these patients with smaller tumors.

For patients with clinical stage IB2 or IIA2 tumors who are treated with definitive radiation, concurrent cisplatin-containing chemotherapy has been shown to significantly improve patient survival. The panel recommends definitive EBRT with concurrent cisplatin-containing chemotherapy and brachytherapy (traditionally 75-80 Gy to total point A. dose). Again, treatment should be modified based on normal tissue tolerance, fractionation, and size of target volume. Primary chemoradiation has a category 1 recommendation [see Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer].

For stage IB2 or IIA2 tumors, the panel had a major disagreement about recommending adjuvant hysterectomy (category 3) (also known as completion surgery) after primary chemoradiation. Adjuvant hysterectomy after RT has been shown to improve pelvic control, but not overall survival, and is associated with increased morbidity. A recent Cochrane review examined whether the addition of hysterectomy to standard non-surgical treatments benefitted women with locally advanced cervical cancer, finding insufficient data to demonstrate a survival benefit associated with surgery. The morbidity is higher after completion surgery, but this may be reduced using a laparoscopic technique. While routine completion hysterectomy is not typically performed, this approach may be considered in patients whose extent of disease or uterine anatomy precludes adequate coverage by brachytherapy.

Advanced Disease

This category has traditionally included patients with stage IIB to IVA disease (ie, locally advanced disease). However, many oncologists now include patients with IB2 and IIA2 disease in the advanced disease category. For patients with more advanced tumors who are undergoing primary chemoradiation, the volume of RT is critical and guided by assessment of nodal involvement in the pelvic and para-aortic nodes. Radiologic imaging studies (including PET/CT) are recommended for stage IB2 or greater disease, especially for evaluation of nodal or extrapelvic tumor (see Principles of Imaging in the NCCN Guidelines for Cervical Cancer). MRI is useful to describe local disease extent and assist in radiation treatment planning. However, needle biopsy of extraterine abnormality can be considered for questionable imaging findings. Surgical staging (ie, extraperitoneal or laparoscopic lymph node dissection) is also an option (category 2B) for these patients. Surgical staging may also detect microscopic nodal disease that is not discernable with radiologic imaging.

For patients without nodal disease or with disease limited to the pelvis only through surgical staging, treatment consists of pelvic EBRT with concurrent cisplatin-based chemotherapy and brachytherapy (category 1). Currently, acceptable, concurrent, cisplatin-based regimens include either weekly cisplatin or the combination of cisplatin/5-FU given every 3 to 4 weeks during RT. An international phase III randomized trial reported that concurrent cisplatin/gemcitabine and EBRT followed by 2 additional cycles of cisplatin/gemcitabine after RT improved PFS and overall survival when compared with a standard regimen of concurrent cisplatin with pelvic EBRT. However, this trial is controversial because of changes in its statistical design and because the reported superior regimen of concurrent cisplatin/gemcitabine and EBRT has unresolved toxicity issues.
However, for patients with positive para-aortic and pelvic lymph nodes by imaging, imaging workup for metastatic disease is recommended. Extraperitoneal lymph node dissection should be considered followed by extended-field EBRT, concurrent cisplatin-containing chemotherapy, and brachytherapy (see Primary Treatment in the NCCN Guidelines for Cervical Cancer). Patients with positive para-aortic lymph nodes who are positive for distant metastases are treated with systemic chemotherapy (see Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines) with (or without) individualized EBRT.187

**Metastatic Disease**

For patients who present with distant metastatic disease (ie, stage IVB), primary treatment is often cisplatin-based chemotherapy (see Therapy for Metastatic Disease in this Discussion). In these situations, individualized EBRT may be considered for control of pelvic disease and other symptoms.187

**Adjuvant Treatment**

Adjuvant treatment is indicated after radical hysterectomy depending on surgical findings and disease stage. Observation is appropriate for patients with stage IA2, IB1, or IIA1 disease who have negative nodes, negative margins, negative parametria, and no cervical risk factors after radical hysterectomy (Sedlis Criteria). However, adjuvant treatment is indicated after radical hysterectomy if pathologic risk factors are discovered.

Pelvic EBRT is recommended (category 1) with (or without) concurrent cisplatin-based chemotherapy (category 2B for chemotherapy) for patients with stage IA2, IB1, or IIA1 disease who have negative lymph nodes after surgery but have large primary tumors, deep stromal invasion, and/or LVSI (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer, Sedlis Criteria).188-192

Adjuvant pelvic RT alone versus no further therapy was tested in a randomized trial (GOG 92) of selected patients with node-negative stage IB carcinoma of the cervix after hysterectomy and pelvic lymphadenectomy.192 Patients were considered to have “intermediate-risk” disease and were eligible for this trial if they had at least 2 of the following risk factors (commonly referred to as “Sedlis Criteria”): 1) greater than one-third stromal invasion; 2) capillary lymphatic space involvement; or 3) cervical tumor diameters more than 4 cm. Patients with positive lymph nodes or involved surgical margins were excluded. At 2 years, the recurrence-free rates were 88% for adjuvant RT versus 79% for the no-adjuvant-treatment group. After long-term follow-up (12 years), an updated analysis confirmed that adjuvant pelvic RT increased PFS; a clear trend towards improved overall survival was noted (P = .07).188 The role of concurrent cisplatin/RT in patients with intermediate-risk disease is currently being evaluated in an international phase III randomized trial (GOG 263, NCT01101451).

Potentially important risk factors for recurrence may not be limited to the “Sedlis Criteria” (ie, > one-third stromal invasion, LVSI, tumor size). Additional risk factors for consideration include tumor histology (eg, adenocarcinoma component)193,194 and close or positive surgical margins.160,195 A recent study has identified a “four-factor model” of intermediate risk factors that was predictive of recurrence in a cohort of 2158 patients with stage IB to IIA cervical cancers; predictive risk factors identified included tumor size ≥3 cm, deep stromal invasion of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology.193 Among these patients, presence of any 2 factors was useful for predicting recurrence after radical hysterectomy.
Postoperative pelvic EBRT with concurrent cisplatin-containing chemotherapy (category 1) \(^{140}\) with (or without) vaginal brachytherapy is recommended for patients with positive pelvic nodes, positive surgical margin, and/or positive parametrium; these patients are considered to have “high-risk” disease (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer). Vaginal brachytherapy may be a useful boost for those with positive vaginal mucosal margins. Adjuvant concurrent chemoradiation significantly improves overall survival for patients with high-risk, early-stage disease (those with positive pelvic nodes, parametrial extension, and/or positive margins) who undergo radical hysterectomy and pelvic lymphadenectomy. \(^{140}\) The Intergroup trial 0107/GOG 109 showed a statistically significant benefit of adjuvant pelvic radiation with concurrent cisplatin and 5-FU in the treatment of patients with stage IA2, IB, or IIA disease who had positive lymph nodes, positive margins, and/or microscopic parametrial involvement found at surgery. \(^{140}\) A recent study re-evaluated these findings from GOG 109 in a population-based cohort (n = 3053) in the National Cancer Database, confirming the survival benefit of adjuvant chemoradiation but suggesting that this benefit may be best realized in patients with lymph node involvement. \(^{196}\) Depending on the results of primary surgery, imaging may be recommended to determine whether distant metastases are present. In women who are positive for distant metastases, biopsy of suspicious areas should be considered as indicated (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer). For patients without distant metastases, recommended treatment is extended-field EBRT (including pelvic and para-aortic lymph nodes) with concurrent cisplatin-based chemotherapy and with (or without) brachytherapy. For patients with distant metastases, recommended treatment is systemic chemotherapy (see Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines) with (or without) individualized EBRT. \(^{187}\) Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer \(^{192,195}\) or locally-advanced cervical cancer. \(^{200,201}\) A meta-analysis of data on patients with stage IB1 to IIA cervical cancer found that neoadjuvant chemotherapy may reduce the need for adjuvant RT by decreasing tumor size and metastases, but indicated no overall survival benefit. \(^{201}\) However, data from a second meta-analysis suggested that response to neoadjuvant chemotherapy was a strong prognostic factor for PFS and overall survival. \(^{202,203}\) Outside of the clinical trial, the panel does not recommend the use of neoadjuvant chemotherapy.

**Surveillance**

The panel agrees with the new Society of Gynecologic Oncology’s recommendations for post-treatment surveillance. \(^{204}\) The recommended surveillance is based on the patient’s risk for recurrence and personal preferences. History and physical examination is recommended every 3 to 6 months for 2 years, every 6 to 12 months for another 3 to 5 years, and then annually (see Surveillance in the NCCN Guidelines for Cervical Cancer). Patients with high-risk disease can be assessed more frequently (eg, every 3 months for the first 2 years) than patients with low-risk disease (eg, every 6 months).

Annual cervical/vaginal cytology tests can be considered as indicated for detection of lower genital tract dysplasia (eg, for those who have had fertility-sparing surgery). Some clinicians have suggested that rigorous cytology follow-up is not warranted because of studies stating that Pap smears did not detect recurrences in patients with stage I or II cervical cancer who were asymptomatic after treatment. \(^{204-206}\) Noting the
inherent differences between these patients and the general screening population, the panel does not recommend workup of low-grade squamous dysplasia detected during surveillance, but suggests that patients should follow up with a provider with specific expertise in this area. It is important to emphasize good clinical evaluation and a high index of suspicion, because the detection rate of recurrent cervical cancer is low using cervical and vaginal cytology alone.207

For patients with stage I disease, follow-up imaging should be based on symptomatology and clinical concern for recurrent/metastatic disease, such as abnormal physical exam finding or new pelvic, abdominal, or pulmonary symptoms. If fertility sparing treatment was provided, pelvic MRI should be considered 6 months after surgery and yearly for 2 to 3 years. PET/CT can be considered if metastasis is suspected. For patients with stage II disease or greater, PET/CT (preferred) or CT should be performed within 3 to 6 months of completing therapy, pelvic MRI is optional. Additional imaging should be guided by symptomatology and clinical concern for recurrent/metastatic disease. Specific indications and recommendations for surveillance imaging are detailed in Principles of Imaging in the NCCN Guidelines for Cervical Cancer.204,208-216

Many other tests remain optional based on clinical indications, such as semiannual CBCs, blood urea nitrogen, and serum creatinine determinations (see Surveillance in the NCCN Guidelines for Cervical Cancer). Patients with persistent or recurrent disease need to be evaluated using additional imaging studies as clinically indicated and surgical exploration in selected cases followed by therapy for relapse (see next section).217

Patient education regarding symptoms suggestive of recurrence is recommended (e.g., vaginal discharge; weight loss; anorexia; pain in the pelvis, hips, back, or legs; persistent coughing). Patients should also be counseled on healthy lifestyle, obesity, nutrition, exercise, sexual health, and potential long-term and late effects of treatment. Smoking cessation and abstinence should be encouraged.204 See the NCCN Guidelines for Survivorship, the NCCN guidelines for Smoking Cessation, and http://www.cancer.org/treatment/survivorship).

Patients who have received RT for cervical cancer may experience vaginal stenosis and dryness and should receive education on important issues regarding sexual health and vaginal health. Providers should inform patients about regular vaginal intercourse and/or vaginal dilator use and on the use of vaginal moisturizers/lubricants (e.g., estrogen creams). Anecdotal evidence suggests that vaginal dilators may be used to prevent or treat vaginal stenosis.218 Dilator use can start 2 to 4 weeks after RT is completed and can be performed indefinitely (http://www.mskcc.org/patient_education/_assets/downloads-english/571.pdf).

Cervical cancer survivors are at risk for second cancers.219 Data suggest that patients who undergo RT for pelvic cancers are at risk for radiation-induced second cancers, especially at radiated sites near the cervix (e.g., colon, rectum/anus, urinary bladder); therefore, careful surveillance is appropriate for these patients.220,221

**Therapy for Relapse**

Recurrences should be proven by biopsy before proceeding to treatment planning for recurrent disease.

**Locoregional Therapy**

Patients with a localized recurrence of cervical cancer after initial treatment may be candidates for radical retreatment; options include: 1) RT and/or chemotherapy; or 2) surgery.229,222 After treatment for relapse,
long-term, disease-free survival rates of approximately 40% have been reported in some situations.\(^{223}\)

For patients who experience locoregional recurrences who have not undergone previous RT or who experience recurrences outside of the previously treated RT field, therapy for relapse includes tumor-directed EBRT with (or without) chemotherapy and/or brachytherapy; surgical resection can be considered if feasible (see Therapy for Relapse in the NCCN Guidelines for Cervical Cancer). Typically, the chemoradiation for recurrence uses cisplatin as a single agent or cisplatin plus 5-FU.\(^{224,225}\) However, in those patients who have relapsed soon after completing initial chemoradiation with these regimens, alternative concurrent chemotherapy agents such as carboplatin, paclitaxel, and gemcitabine may be considered.

Patients with central pelvic recurrent disease after RT should be evaluated for pelvic exenteration, with (or without) intraoperative RT (IORT), although IORT is category 3.\(^{226-233}\) Surgical mortality is generally 5% or less, with survival rates approaching 50% in carefully selected patients.\(^{229}\) Concomitant measures with these radical procedures include adequate rehabilitation programs dealing with the psychosocial and psychosexual consequences of the surgery as well as reconstructive procedures.\(^{228,234-236}\) Although exenteration is the common surgical approach in postradiation patients with isolated central pelvic relapse, radical hysterectomy or brachytherapy may be an option in carefully selected patients with small central lesions (<2 cm).

For patients with noncentral recurrent disease, options include EBRT with (or without) chemotherapy, resection with (or without) IORT (category 3 for IORT), chemotherapy, best supportive care (see the NCCN Guidelines for Palliative Care), or participation in a clinical trial. Patients who experience recurrence after second-line definitive therapy, either surgery or RT, have a poor prognosis. They can be treated with chemotherapy or best supportive care, or can be enrolled in a clinical trial.

**Therapy for Metastatic Disease**

Patients who develop distant metastases, either at initial presentation or at relapse, are rarely curable. For highly selected patients with isolated distant metastases amendable to local treatment, occasional long-term survival has been reported with: 1) surgical resection with (or without) EBRT; 2) Local ablative therapies with (or without) EBRT; or 3) EBRT with (or without) chemotherapy (see Therapy for Relapse in the NCCN Guidelines for Cervical Cancer). Systemic adjuvant chemotherapy can be considered. For example, patients who may benefit from aggressive local therapy for oligometastatic disease include those with nodal, lung, liver, or bone metastases. Following local therapy, additional adjuvant chemotherapy can be considered. For most other patients with distant metastases, an appropriate approach is a clinical trial, chemotherapy (see Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines for Cervical Cancer), or best supportive care (see NCCN Guidelines for Palliative Care at www.NCCN.org).

The palliation of pelvic recurrences in heavily irradiated sites that are not amenable to local pain control techniques or to surgical resection is difficult. These sites are generally not responsive to chemotherapy. Adequately palliating the complications of pain and fistulae from these recurrences is clinically challenging (http://emedicine.medscape.com/article/270646-overview). However, short courses of RT may provide symptomatic relief to patients with bone metastases, painful para-aortic nodes, or supraclavicular adenopathy.\(^{187,237,238}\)
Chemotherapy is often recommended for patients with extrapelvic metastases or recurrent disease who are not candidates for RT or exenterative surgery. Patients whose disease responds to chemotherapy may have relief from pain and other symptoms. If cisplatin was previously used as a radiosensitizer, combination platinum-based regimens are preferred over single agents in the metastatic disease setting based on several randomized phase III trials (see next paragraph). However, responses to chemotherapy are often of short duration and survival is rarely increased.

**First-Line Combination Chemotherapy**

Cisplatin has been considered the most effective agent for metastatic cervical cancer. However, most patients who develop metastatic disease have received concurrent cisplatin/RT as primary treatment and may no longer be sensitive to single-agent platinum therapy. Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel/bevacizumab (category 1), cisplatin/paclitaxel (category 1), and cisplatin/topotecan (category 2A), have been extensively investigated in clinical studies. A randomized phase III study (GOG 169) in 264 patients compared cisplatin/paclitaxel versus cisplatin alone for metastatic, recurrent, or persistent cervical cancer. Patients receiving the 2-drug combination had a higher response rate (36% vs. 19%) and improved PFS (4.8 months vs. 2.8 months; \( P > .001 \)) compared to single-agent cisplatin, although no improvement was seen in median survival. Patients who responded to cisplatin/paclitaxel had a significant improvement in quality of life.

Another randomized phase III study (GOG 179) in 294 patients investigated cisplatin/topotecan versus cisplatin alone for recurrent or persistent cervical cancer. The topotecan combination regimen was shown to be superior to single-agent cisplatin with respect to overall response rate (27% vs. 13%, \( P = .004 \)), PFS (4.6 months vs. 2.9 months; \( P = .014 \)), and median survival (9.4 months vs. 6.5 months; \( P = .017 \)). The FDA (Food and Drug Administration) has approved cisplatin/topotecan for advanced cervical cancer. However, the cisplatin/paclitaxel or carboplatin/paclitaxel regimens are less toxic and easier to administer than cisplatin/topotecan.

A phase III trial (GOG 204) compared 4 cisplatin-doublet regimens (cisplatin/paclitaxel, cisplatin/topotecan, cisplatin/gemcitabine, and cisplatin/vinorelbine) in 513 patients with advanced metastatic or recurrent cancer. The trial was closed early based on futility analysis, because it was apparent that the cisplatin/topotecan, cisplatin/gemcitabine (category 3), and cisplatin/vinorelbine regimens were not superior to the control arm of cisplatin/paclitaxel. No significant differences in overall survival were seen; however, the trends for response rate, PFS, and overall survival (12.9 months vs. 10 months) suggest that cisplatin/paclitaxel is superior to the other regimens. Cisplatin/paclitaxel was associated with less thrombocytopenia and anemia (but with more nausea, vomiting, infection, and alopecia) than the other regimens.

A recent randomized phase III trial (GOG 240) studied the addition of bevacizumab to combination chemotherapy regimens (cisplatin/paclitaxel/bevacizumab or topotecan/paclitaxel/bevacizumab) in 452 patients in the first-line setting of metastatic, persistent, or recurrent cervical cancer. An analysis of pooled data from the two chemotherapy regimens revealed significant improvements in overall survival among patients receiving bevacizumab (17.0 months vs. 13.3 months; \( P = .004 \)). While topotecan/paclitaxel (category 2A) was not shown to be superior to cisplatin/paclitaxel, it may be considered as an alternative in patients who are not candidates for cisplatin. While bevacizumab led to higher toxicity (eg, hypertension, thromboembolic events, and gastrointestinal fistula), it was not associated with a
statistically significant decrease in patient-reported quality of life ($P = .27$). Based on these data, the FDA approved bevacizumab as part of combination therapy with paclitaxel and either cisplatin or topotecan for treating persistent, recurrent, or metastatic cervical cancer. The panel has accepted both bevacizumab-containing regimens as category 1 options for treating persistent, recurrent, or metastatic cervical cancer.

Recently published data from a phase III randomized trial (JCOG0505) suggested that carboplatin/paclitaxel is non-inferior to cisplatin/paclitaxel in 253 women with metastatic or recurrent cervical cancer. Many physicians use carboplatin/paclitaxel because of ease of administration and tolerability. Results from JCOG0505 showed that the carboplatin/paclitaxel (TC) regimen was non-inferior to cisplatin/paclitaxel (TP) in terms of median overall survival (18.3 months for TP vs. 17.5 months for TC; HR=0.994 (90% CI, 0.79 to 1.25); $P = .032$) and non-hospitalization periods were significantly longer for patients receiving TC. However, among patients who had not received prior cisplatin, OS for TC and TP was 13.0 and 23.2 months, respectively (HR=1.571; 95% CI, 1.06 to 2.32). Based on these data, the panel recommends carboplatin/paclitaxel as a category 1 option for patients who have received prior cisplatin therapy. Carboplatin/paclitaxel is a category 2A recommendation for other indications (ie, for patients who have not received prior platinum-based therapy).

A recent systematic review of the data on cisplatin/paclitaxel and carboplatin/paclitaxel regimens also suggested that lower toxicity carboplatin-based regimens appear to be an equally effective alternative to cisplatin-based regimens for treating recurrent or metastatic cervical cancer. Based on the collective findings from GOG 240 and JCOG0505, the panel has opted to include carboplatin/paclitaxel/bevacizumab as an additional treatment option for recurrent or metastatic cervical cancer (category 2A). Based on the previous studies, cisplatin/paclitaxel and carboplatin/paclitaxel have become the most widely used systemic regimens for metastatic or recurrent cervical cancer. However, for patients who may not be candidates for taxanes, cisplatin/topotecan and cisplatin/gemcitabine remain reasonable alternative regimens. Nonplatinum regimens are also being studied and may be considered in patients who cannot tolerate platinum-based chemotherapy.

**Single Agents**

Cisplatin is generally regarded as the most active agent and is recommended as a first-line single-agent chemotherapy option for recurrent or metastatic cervical cancer; reported response rates are approximately 20% to 30%, with an occasional complete response. Overall survival with cisplatin is approximately 6 to 9 months. Both carboplatin and paclitaxel have each been reported to be tolerable and efficacious and are also possible first-line single-agent chemotherapy. Therefore, palliation with single agents—cisplatin, carboplatin, or paclitaxel—is a reasonable approach in patients with recurrent disease not amenable to surgical or radiotherapeutic approaches.

Other agents (that are category 2B unless otherwise indicated) that have shown responses or prolongation of PFS and may be useful as second-line therapy include bevacizumab, docetaxel, 5-FU, gemcitabine, ifosfamide, irinotecan, mitomycin, albumin-bound paclitaxel (ie, nab-paclitaxel), topotecan, pemetrexed, and vinorelbine.

**Drug Reactions**

Virtually all drugs have the potential to cause adverse reactions, either during or after infusion. In cervical cancer treatment, drugs that more
commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, and paclitaxel. Most of these drug reactions are mild infusion reactions (e.g., skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (e.g., life-threatening anaphylaxis) can occur. In addition, patients can have severe infusion reactions and mild allergic reactions. Infusion reactions are more common with paclitaxel. Allergic reactions (i.e., true drug allergies) are more common with platinum agents (e.g., cisplatin).

Management of drug reactions is discussed in the NCCN Guidelines for Ovarian Cancer. Importantly, patients who experienced severe life-threatening reactions should not receive the implicated agent again unless evaluated by an allergist or specialist in drug desensitization. If a mild allergic reaction previously occurred and it is appropriate to re-administer the drug, a desensitization regimen is recommended even if the symptoms have resolved. Various desensitization regimens have been published and should be followed. Patients must be desensitized with each infusion if they have had a previous reaction. Almost all patients can be desensitized. To maximize safety, patients should be desensitized in the intensive care unit.

**Other Agents**

Vaccine therapies currently have no established role in the treatment of cervical cancer at the present time, except in the setting of a clinical trial. Targeted therapy (using small molecules or monoclonal antibodies) is currently used in various clinical trials.

**Best Supportive Care**

Patients with refractory systemic cancer warrant a comprehensive coordinated approach involving hospice care, pain consultants, and emotional and spiritual support, individualized to the situation (see the NCCN Guidelines for Palliative Care).

**Incidental Cervical Cancer**

Invasive cervical carcinoma is sometimes found incidentally after extraperitoneal hysterectomy. Workup for these patients includes history and physical examination, CBC (including platelets), and liver and renal function tests. Recommended radiologic imaging includes chest radiography, CT, or combined PET/CT; MRI may be performed if indicated to rule out gross residual disease. However, imaging is optional for patients with stage IB1 or smaller tumors (see *Incidental Finding of Invasive Cervical Cancer at Simple Hysterectomy* in the NCCN Guidelines for Cervical Cancer).

No definitive data are available to guide the appropriate adjuvant treatment of these patients. Surveillance is recommended for patients with stage IA1 cervical cancer who do not have LVSI. For patients with either stage IA1 with LVSI or with stage IA2 or higher tumors (pathologic findings), the panel believes that a reasonable treatment schema should be based on the status of the surgical margins. If margins are positive and imaging is negative for nodal disease, then pelvic RT with concurrent cisplatin-containing chemotherapy with (or without) individualized brachytherapy is recommended (see *Primary Treatment* in the NCCN Guidelines for Cervical Cancer).

If margins or imaging is negative in stage IA2 or greater tumors, options include: 1) pelvic RT with (or without) concurrent cisplatin-containing chemotherapy and brachytherapy; or 2) a complete parametrectomy, upper vaginectomy, and pelvic lymph node dissection with (or without) para-aortic lymph node sampling. Typically, observation is recommended for patients with negative lymph nodes. However, pelvic radiation with (or without) vaginal brachytherapy is an option if they
have high-risk factors (ie, large primary tumor, deep stromal invasion, LVSI) (see Primary Treatment in the NCCN Guidelines for Cervical Cancer). Concurrent cisplatin-based chemoradiation is recommended for gross residual disease, positive imaging, disease in the lymph nodes and/or parametrium, and/or a positive surgical margin; individualized brachytherapy is clearly indicated for a positive vaginal margin.

Radiation Therapy

RT is often used in the management of patients with cervical cancer either 1) as definitive therapy for those with locally advanced disease or for those who are poor surgical candidates; or 2) as adjuvant therapy following radical hysterectomy for those who have one or more pathologic risk factors (eg, positive lymph nodes, parametrial infiltration, positive surgical margins, large tumor size, deep stromal invasion, LVSI).

The algorithm provides general RT dosage recommendations, which are expanded in the Principles of Radiation Therapy (see the NCCN Guidelines for Cervical Cancer). These RT dosages should not be interpreted as stand-alone recommendations, because RT techniques and clinical judgment are an essential part of developing an appropriate treatment regimen.

Optimum staging of disease to precisely delineate the primary tumor volume and draining lymph nodes, including abdominopelvic radiologic studies (CT, MRI, or combined PET/CT scans), is recommended in patients with stage IB2, IIA2, or advanced-stage tumors. Contemporary imaging studies must be correlated with careful assessment of clinical findings to define tumor extent, especially with regard to vaginal or parametrial extension.

Radiation Treatment Planning

Technologic advances in imaging, computer treatment planning systems, and linear accelerator technology have enabled the more precise delivery radiation doses to the pelvis. However, physical accuracy of dose delivery must be matched to a clear understanding of tumor extent, potential pathways of spread, and historical patterns of locoregional recurrence to avoid geographic misses.

CT-based treatment planning with conformal blocking and dosimetry is considered standard care for external-beam RT. Brachytherapy is a critical component of definitive therapy in patients with cervical cancer who are not candidates for surgery (ie, those with an intact cervix); it may also be used as adjuvant therapy. Brachytherapy is typically combined with external-beam radiation in an integrated treatment plan. MRI imaging immediately preceding brachytherapy may be helpful in delineating residual tumor geometry. Stereotactic body radiotherapy (SBRT) allows delivery of very high doses of focused external beam radiation and may be applied to isolated metastatic sites.

Routine image guidance, such as cone-beam CT (CBCT), may be helpful in defining daily internal soft tissue positioning. Concepts regarding the gross target volume (GTV), clinical target volume (CTV), planning target volume (PTV), organs at risk (OARs) and dose-volume histogram (DVH) have been defined for use in conformal radiotherapy, especially for IMRT.

Point A, representing a paracervical reference point, has been the most widely used, validated, and reproducible dosing parameter used to date. However, limitations of the Point A dosing system include the fact that it does not take into account the three-dimension shape of tumors, nor individual tumor to normal tissue structure correlations. There are increasing efforts to use and standardize image-based volumetric...
brachytherapy approaches using MR, CT or ultrasound - international validation efforts are underway (EMBRACE, NCT00920920).\textsuperscript{293-295}

For patients with locally advanced cancers, initial radiation treatment of 40 to 45 Gy to the whole pelvis is often necessary to obtain tumor shrinkage to permit optimal intracavitary placements. With low-dose-rate intracavitary systems, total doses from brachytherapy and external-beam radiation to point A of at least 80 Gy are currently recommended for small tumors, with doses of 85 Gy or higher recommended for larger tumors (http://www.americanbrachytherapy.org/guidelines/cervical_cancer_task_group.pdf).\textsuperscript{129}

For lesions in the lower one third of the vagina, the inguinal lymph nodes must be treated. The use of extended-field radiation to treat occult or macroscopic para-aortic lymph node disease must be carefully planned to ensure an adequate dose (45 Gy for microscopic disease) without exceeding bowel, spinal cord, or renal tolerances.\textsuperscript{296} General recommendations for radiation volumes and doses are discussed in the algorithm (see Principles of Radiation Therapy for Cervical Cancer in the NCCN Guidelines for Cervical Cancer).

Intensity-modulated RT (IMRT) is becoming more widely available; however, issues regarding target definition, patient and target immobilization, tissue deformation, toxicity and reproducibility remain to be validated.\textsuperscript{297-304} Initial phase II hematologic toxicity data from RTOG 418 suggested that limiting the volume of bone marrow treated with IMRT was an important consideration for patients with cervical cancer who were receiving concurrent chemotherapy.\textsuperscript{305} The ongoing TIME-C trial (RTOG 1203, NCT01672892) is comparing post-hysterectomy patients receiving adjuvant IMRT or standard (3D) RT to determine whether IMRT reduces acute gastrointestinal toxicity.\textsuperscript{306}

Several retrospective analyses suggest that prolonged RT treatment duration has an adverse effect on outcome.\textsuperscript{307-311} Extending the overall treatment beyond 6 to 8 weeks can result in approximately a 0.5% to 1% decrease in pelvic control and cause specific survival for each extra day of overall treatment time. Thus, although no prospective randomized trials have been performed, it is generally accepted that the entire RT course (including both external-beam RT and brachytherapy components) should be completed in a timely fashion (within 8 weeks); delays or splits in the radiation treatment should be avoided whenever possible.

Normal Tissue Considerations

Planning for RT in cervical cancer must take into account the potential impact on surrounding critical structures, such as rectum, bladder, sigmoid, small bowel, and bone. Acute effects (ie, diarrhea, bladder irritation, fatigue) occur to some degree in most patients undergoing radiation and are typically magnified by concurrent chemotherapy. However, acute effects can often be managed with medications and supportive care, and they generally resolve soon after completion of radiation. To avoid treatment-related menopause, ovarian transposition can be considered before pelvic RT in select young patients (<45 years with early-stage disease).\textsuperscript{134-136}

After therapy for cervical cancer, late side effects may include potential injury to bladder, rectum, bowel, and pelvic skeletal structures.\textsuperscript{312} The risk of major complications (eg, obstruction, fibrosis/necrosis, and fistula) is related to the volume, total dose, dose per fraction, and specific intrinsic radiosensitivity of the normal tissue that is irradiated.\textsuperscript{296,313,314} Careful blocking in order to minimize normal tissue exposure while maintaining tumor coverage is critical for optimal outcomes. In addition, patient-related conditions (ie, inflammatory bowel...
disease, collagen-vascular disease, multiple abdominal/pelvic surgeries, history of pelvic inflammatory disease, diabetes) influence determination of radiation dose and volumes.

For most patients, it is generally accepted that the whole pelvis can tolerate an external-beam radiation dose of 40 to 50 Gy. Gross disease in the parametria or unresected nodes may be treated with tightly contoured external-beam boosts to 60 to 65 Gy. Intracavitary brachytherapy boosts require attention to proper placement of the applicators within the uterus and against the cervix and vaginal apex, as well as appropriate packing to maximally displace the bladder and rectum. SBRT is not considered an appropriate routine alternative to brachytherapy.

Cervical Cancer and Pregnancy

Cervical cancer is the most frequently diagnosed gynecologic malignancy in pregnant women; however, most women have stage I disease. Invasive cervical cancer during pregnancy creates a clinical dilemma and requires multidisciplinary care. Women must make the difficult decision either to delay treatment until documented fetal maturity or to undergo immediate treatment based on their stage of disease. Women who delay treatment until fetal maturity should have their children delivered by cesarean section. Radical trachelectomy with preservation of pregnancy has been successfully performed in a few pregnant patients with early-stage cervical cancer.

Patients with early-stage disease may prefer to have radical hysterectomy and node dissection instead of RT to avoid radiation fibrosis and to preserve their ovaries. Patients with Stage I disease who delay treatment until fetal maturity can undergo cesarean section with concurrent radical hysterectomy and pelvic node dissection. For those choosing RT, traditional RT with (or without) chemotherapy protocols (described previously) may need to be modified.

Summary

Cervical cancer is decreasing in the United States because of the wide use of screening; however, it is increasing in developing countries (~275,000 deaths/year), because screening is not available to many women. Effective treatment for cervical cancer (including surgery and concurrent chemoradiation) can yield cures in 80% of women with early-stage disease (stages I–II) and in 60% of women with stage III disease. The hope is that immunization against HPV (using vaccines) will prevent persistent infection with the types of HPV against which the vaccine is designed, and will therefore prevent specific HPV cancer in women.
### Table 1:
Estimates of the Relative Risk of Death in Five Clinical Trials of Concurrent Chemotherapy and Radiotherapy

<table>
<thead>
<tr>
<th>Study*</th>
<th>FIGO Stage</th>
<th>Control Group</th>
<th>Comparison Group</th>
<th>Relative Risk of Death in Comparison Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keys et al.†</td>
<td>IB2</td>
<td>Radiotherapy</td>
<td>Radiotherapy plus weekly cisplatin</td>
<td>0.54</td>
</tr>
<tr>
<td>Rose, Bundy, Watkins et al.†</td>
<td>IIB-IVA</td>
<td>Radiotherapy plus hydroxyurea</td>
<td>Radiotherapy plus weekly cisplatin</td>
<td>0.61</td>
</tr>
<tr>
<td>Morris et al.†</td>
<td>IB2-IVA</td>
<td>Extended-field radiotherapy</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.52</td>
</tr>
<tr>
<td>Whitney et al.</td>
<td>IIB-IVA</td>
<td>Radiotherapy plus hydroxyurea</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.72</td>
</tr>
<tr>
<td>Peters et al.</td>
<td>IB or IIA (selected postoperatively)</td>
<td>Radiotherapy</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.50</td>
</tr>
</tbody>
</table>


*See Discussion for all references.

†These studies have been updated (see Discussion).

Used with permission from Thomas GM. Improved treatment for cervical cancer concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340(15):1198-1200. Copyright© 1999 Massachusetts Medical Society. All rights reserved.
References


15. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality


186. Rose PG, Degeest K, McMeekin S, Fusco N. A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology...


270. Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in


285. Tinker AV, Ellard S, Welch S, et al. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or


